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1 Introduction 
The discovery of antibiotics, the increasing use of vaccination and improving neonatal care 
in the 20th century led to an increased life expectancy from 50 years to currently more than 
80 years in developed countries. Consequently, the focus of practitioners and medical 
research shifted from infectious diseases to age related disorders whose incidence and 
prevalence increased dramatically with increasing life expectancy. This includes among others 
ischemic cardiovascular diseases, cancer and neurodegenerative diseases (ND) (Niccoli and 
Partridge 2012; Lunenfeld and Stratton 2013). Investigating ND is particularly interesting as 
the affected neurons are post-mitotic cells. They cannot replicate, have limited abilities to 
regenerate and can thus be a limiting factor of life expectancy and quality of life in ND such 
as Alzheimer’s disease (AD) or Parkinson’s disease (PD). These two most common ND are 
chronic progressive diseases affecting predominantly elderly people and consequently show 
increasing incidence and prevalence due to the demographic changes (Savica et al. 2016). The 
movement disorder PD is diagnosed based on clinical symptoms without objective disease 
specific biomarkers. It can only be treated symptomatically without possibilities to prevent 
disease progression. Pathophysiologically, PD is hallmarked by a loss of dopaminergic 
projections from the midbrain to the striatum. However, the reasons for this neuron loss are 
still unclear. Other regions, however, are also affected at different times during disease 
development. 
A new field of research was opened by the discovery of various epigenetic influences 
determining the phenotype of cells and organisms besides their pure sequence of the 
deoxyribonucleotide acid (DNA) – their genome. In this context, microRNA (miRNA,  
RNA = ribonucleotide acid) regulating gene expression by inhibition of protein translation 
were described. Just as several other epigenetic mechanisms, they can be influenced by the 
environment and their alterations can be partially inherited. They are investigated as putative 
biomarkers, parts of pathomechanisms and are putative therapeutic agents or targets in PD 
and many other diseases (Waddington 2012; Chakraborty et al. 2017; Roser et al. 2018a).  
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1.1 Parkinson’s disease 
1.1.1 Different types of Parkinsonian syndromes 
The French neurologist Jean-Martin Charcot (1825-1893) first suggested the term 
“Parkinson’s disease” for the syndrome (a set of symptoms) James Parkinson described in 
“An Essay on the Shaking Palsy” in 1817. Parkinson’s report characterized bradykinesia, 
rigidity, tremor and postural and gait impairment as the cardinal symptoms of a disease that 
he observed in six patients, some of which he could not even examine. Charcot later 
described the clinical features much more exactly, identified clinical subtypes and 
distinguished PD from multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). 
Different diseases can clinically appear with a Parkinsonian syndrome (Goetz 2011; Mhyre 
et al. 2012; Jankovic 2015). 
Idiopathic Parkinson’s Disease is the more precise name for a Parkinsonian syndrome 
which is not inherited and cannot be attributed to any secondary disease-causing reasons. It 
is the most frequent (~ 80%) diagnosis for patients with Parkinson’s syndrome (Dauer and 
Przedborski 2003; Mhyre et al. 2012). 
Monogenic (or familial) Parkinsonian syndrome due to specific monogenetic changes 
and its inheritance follows Mendelian Laws. It is estimated that 5 % - 10 % of all PD cases 
can be explained by monogenic inheritance but 15 % - 20 % have a positive family history 
for PD (Gasser et al. 2011; Nuytemans et al. 2010). Familial PD often stands out with an 
early onset of disease. The different types of inherited PD have specific courses and 
treatment response depending on the responsible gene and mutation. The number of 
affected genes, and genetic risk factors increases constantly (Lill 2016; Zhang et al. 2018; 
Klein and Westenberger 2012; Coppede 2012). 
Atypical Parkinsonian syndromes (aPS) are a group of ND where a Parkinsonian 
syndrome can also be observed. Additionally, patients suffer from subtype specific 
symptoms and often only poorly respond to dopamine replacing therapies. This group 
includes progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal 
degeneration (CBD) and Dementia with Lewy bodies (DLB) (Mitra et al. 2003; Thenganatt 
and Jankovic 2014; Jankovic 2015). 
In cases of secondary Parkinsonian syndrome, the symptoms can be attributed to a 
specific disease-causing reason. Drug induced Parkinsonism is the second-most-common 
reason for a Parkinsonian syndrome – in certain contexts also known as extrapyramidal 
(drug) side effects. Secondary PD may come from treatment with dopamine antagonistic 
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drugs such as lithium, valproic acid, antipsychotics (e.g. chlorpromazine, risperidone), 
antiemetics (e.g. metoclopramide), certain calcium channel blockers (e.g. flunarizine) and 
other drugs (Shin and Chung 2012). Parkinsonism can also be induced by trauma, 
inflammation (e.g. AIDS, encephalopathy), metabolic disorders (e.g. Morbus Wilson, 
Hypoparathyroidism) or toxins like the pesticides paraquat, rotenone and others (Lee and 
Gilbert 2016). 
Pathologically, neurodegenerative diseases can be classified according to the different protein 
aggregates. PD, MSA and DLB are classified as a α-synucleinopathies. Whereas α-synuclein 
aggregates are found as intraneuronal Lewy bodies in PD and DLB, in MSA they are 
described as inclusion bodies in oligodendroglia. In contrast, PSP, CBD and AD can be 
classified as tauopathies (Mitra et al. 2003; Halliday et al. 2011). 
1.1.2 Epidemiology of Parkinson’s disease 
Among neurodegenerative diseases, PD is the second most common disorder after AD. The 
prevalence of PD in a general unselected population in industrialized countries is about  
0.1 % - 0.4 %. In people older than 60 years it becomes about 1.0 % up to 3.0 % among 
people of 80 years and older (de Rijk et al. 2000). Incidence rates differ between 10 to more 
than 20 per 100,000 people per year (Tysnes and Storstein 2017; Lee and Gilbert 2016; de 
Rijk et al. 1995). With age as a main risk factor for PD and increasing life expectancies 
worldwide, prevalence and incidence of PD are also increasing (Savica et al. 2016). The 
median age of onset of PD symptoms was believed to be about 60 years, with a life time risk 
of developing the disease of 1.5 % (Lees et al. 2009). Recently published studies however 
described a median age of disease onset between 70.6 up to 74 years (Tysnes and Storstein 
2017; Savica et al. 2016). 
Different epidemiological studies have shown a significant higher prevalence and incidence 
in men, about 1.5 to 2.0 times higher than in women. Moreover, age at onset can be later in 
women and the phenotype of PD is often milder than in men. Estrogen is therefore 
controversially discussed as a possible neuroprotective factor. Various disease risk modifying 
factors were identified through epidemiological studies but many of the (exposure 
dependent) risk increasing factors are more linked to secondary PD. On the other hand, 
some of the putative protective factors are even tested for therapeutic potential. (Lee and 
Gilbert 2016; de Lau and Breteler 2006). 
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1.1.3 Pathophysiology and pathogenesis of Parkinson’s disease 
1.1.3.1 Pathophysiology of Parkinson’s disease 
When James Parkinson gave his famous description for the syndrome which was later named 
after him, he suspected the disease’s focus to be in the central nervous system (CNS) most 
likely in the spinal cord or the medulla oblongata (part of the brainstem). He could not imagine 
other CNS parts to be the focus of the disease as he did not observe any sense or intellectual 
impairments (Parkinson 2002). It took until the beginning of the 20th century until a 
degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) of the 
mesencephalon was described in patients with Parkinsonian syndrome (Goedert et al. 2013; 
Lingor et al. 2017). The loss of dopaminergic projections from the SNpc to the striatum 
leads to a reduced disinhibition of the motoric thalamus and subsequently to a general 
inhibition of movement. The more nigrostriatal projections are lost, the stronger the motor 
inhibition and disease symptoms become (Bernheimer et al. 1973; Bertler and Rosengren 
1959, 1966). 
1.1.3.2 Pathogenesis of Parkinson’s disease 
The dysfunction in the motoric coordinating circuit of striatum, substantia nigra and 
thalamus plausibly explain the characteristic motor symptoms observed in PD. However, the 
reasons for the loss of the nigrostriatal projections are not yet elucidated. Mitochondrial 
dysfunction, oxidative stress, protein mishandling and aggregation as well as various 
environmental factors are discussed as possible parts of the pathogenesis of PD. Important 
knowledge on PD pathogenesis is derived from mutations observed in familial PD. Even 
before the loss of dopaminergic neurons was described as a pivotal pathophysiological 
mechanism, the substantia nigra was known as the locus of PD. In 1912, Friedrich Heinrich 
Lewy discovered inclusion bodies in various brain parts of PD patients which were later 
named Lewy bodies. Decades later, a rare type of autosomal dominantly inherited PD was 
attributed to mutations in the α-synuclein gene (SNCA). Shortly thereafter, Spillantini and 
colleagues demonstrated that aggregated α-synuclein is a major component of Lewy bodies 
also in non-familial PD (Goedert et al. 2013; Polymeropoulos et al. 1997; Spillantini et al. 
1997). The distribution of α-synuclein correlates to the clinical disease stage. In early stages, 
only the brainstem and the anterior olfactory nucleus are affected – in later stages, other 
brain areas become affected in a specific order (Braak et al. 2003).  
The disease stage-dependent distribution of α-synuclein led to two hypotheses. First, α-
synuclein spreads through the brain in a prion-like manner. Thus, the disease phenotype 
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should be modeled by α-synuclein inoculation. Cell to cell transmission of α-synuclein was 
already observed in different cell culture models (Angot et al. 2010; Luk et al. 2012). Even in 
fetal human midbrain neurons transplanted into PD patients’ midbrains, α-synuclein was 
detected already four years after transplantation (Chu and Kordower 2010). In contrast to 
true prion diseases like scrapie or Creutzfeldt Jakob Disease (CJD), an infectivity of 
misfolded α-synuclein and a subsequent induction of α-synuclein aggregation, has not yet 
been observed neither in human nor in animal models (Angot et al. 2010). 
The second hypothesis deals with the fact that the spread of α-synuclein seems to have 
starting points – one in the anterior olfactory nucleus and one in the brainstem close to the 
dorsal nucleus of the vagal nerve. Compared to controls, PD patients had more aggregates 
of α-synuclein in the enteral plexus of Auerbach and Meissner (Wakabayashi et al. 1988). 
Furthermore, a Danish cohort study showed a tendency to a reduced risk to develop PD for 
patients who underwent truncal vagotomy (Svensson et al. 2015) – a suspicion that could not 
be confirmed in a similar Swedish cohort (Liu et al. 2017). However, the affection of the 
vagal system correlates well with constipation, hypotension and sleep disorders observed in 
PD patients. Besides, alterations in the gut microbiome are described and even efforts to use 
it as diagnostic biomarker were made (Scheperjans et al. 2015). Both hypotheses indicate that 
PD might be triggered by an exogenous pathogen entering through the enteral system and 
the nose – the dual hit hypothesis (Hawkes et al. 2007). 
It still must be investigated whether or how exactly α-synuclein harms selectively 
dopaminergic neurons, how it is possibly transmitted between cells and how its aggregation 
is induced. Whereas some studies did not observe α-synuclein-induced degeneration or cell 
death (Tompkins and Hill 1997; Parkkinen et al. 2011), most reports described an α-
synuclein-induced impairment of synaptic functions, cytoskeletal remodeling, mitochondria 
or protein degradation subsequently leading to neurodegeneration. Besides, overexpression 
of α-synuclein is frequently used in animal models of PD (Stefanis 2012). A malfunction of 
the protein-degrading ubiquitin proteasome system (UPS) is discussed to be involved in α-
synuclein aggregation as mutations in the UPS related PARKIN gene were observed in 
familial PD. Still, it was also demonstrated that α-synuclein can aggregate independently of 
the UPS (Moore et al. 2003; Kitada et al. 1998; Lim 2007; Giasson and Lee 2003; Sampathu 
et al. 2003). Besides, the discovery of GBA1 mutations – a gene encoding for the lysosomal 
enzyme glucocerebrosidase – as a genetic risk factor for developing PD, has driven the 
attention to lysosomes as a part of PD pathogenesis. Also, the common mutations in LRRK2 
or DJ-1 in familial PD and various other genetic risk factors could be linked to failures in 
lysosomal pathways. For instance, increased levels of oxidized dopamine were reported to 
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lead to an acquired reduction of glucocerebrosidase activity and mitochondrial failure in 
dopaminergic neurons from induced pluripotent stem cells from homozygous DJ-1 mutated 
PD patients. The lysosomal dysfunction is also suspected to be involved in the accumulation 
of α-synuclein in PD patients’ brains (Kilpatrick 2016; Burbulla et al. 2017). 
Apart from that, most mutated genes in familial PD (e.g. PINK1, PARKIN, LRRK2, SNCA) 
can be linked to increased vulnerability and instability of mitochondria and impaired 
degradation (mitophagy). Besides, mitochondrial dysfunction was also observed in sporadic 
PD. Moreover, several cases of secondary Parkinsonism in patients with intravenous drug 
abuse could be attributed to toxins harming mitochondria in dopaminergic neurons. (Davis 
et al. 1979; Langston et al. 1983; Park et al. 2018). The opioid drugs were contaminated with 
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) which was later described to be 
oxidized by astrocytes’ monoaminoxidase type B (MAO-B) to 1-methyl-4-phenylpyridinium 
(MPP+). Through dopamine transporters, MPP+ specifically enters dopaminergic neurons 
and inhibits the mitochondrial complex I, which increases levels of reactive oxygen species (ROS) 
and impairs the cells’ energy supply. Today, complex I inhibitors such as MPP+ or 6-
hydroxydopamine are frequently used in various models of PD (Corsini et al. 1987; Kopin 
1992; Gerlach et al. 1991; Dauer and Przedborski 2003). Mutations in mitochondrial complex 
I could be identified as a risk factor for developing PD but also dementia (Yan et al. 2013). 
Furthermore, complex I inhibition was observed throughout the entire brain of sporadic PD 
patients but the substantia nigra was the only analyzed brain part where it correlated with 
DNA damage (Schapira et al. 1990; Mann et al. 1994; Janetzky et al. 1994). Interestingly, α-
synuclein aggregation was decreased in complex I deficient neurons (Flønes et al. 2018; Dölle 
et al. 2016).  
Possible reasons for the particular vulnerability of dopaminergic neurons to an impaired 
mitochondrial and complex I function might be the constant production of ROS through 
dopamine metabolism (Miyazaki and Asanuma 2008; Hastings 2009). On the other hand, 
dopamine depletion neither protects from MPTP toxicity (Hasbani et al. 2005) nor does 
dopamine replacing therapy accelerate the progression of PD (Fahn 2005). Thus, dopamine 
metabolism is possibly not the major or at least not the only reason for the vulnerability of 
dopaminergic neurons. However, α-synuclein was reported to induce mitochondrial 
fragmentation both in wild type and in different mutants by destabilizing the mitochondrial 
membrane (Ryan et al. 2015; Park et al. 2018). Furthermore, a special type of voltage gated 
calcium channels in SNpc dopaminergic neurons with increased calcium influx was described 
to increases oxidative stress and energy consumption. Interestingly, dihydropyridine calcium 
channel blockers were reported to lower the risk of developing PD. Although, PD patients 
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tend to have low blood pressure, which makes the drugs – normally used to treat 
hypertension – less appropriate for treatment of PD. Clinical trials could however not 
demonstrate a therapeutic effect of dihydropyridine (Kilpatrick 2016). 
Like in various other neurodegenerative diseases an accumulation of iron is observed in PD 
patients’ brains, which however, also increases physiologically with age. Nevertheless, iron 
can induce translation of α-synuclein and probably enhances its aggregation (Lingor et al. 
2017). Moreover, iron is a co-factor of several redox enzymes and its homeostasis is 
important to control ROS as high iron levels can induce oxidative stress and increased iron 
levels can also be involved in mitochondrial damage (Zecca et al. 2004; Park et al. 2018). 
Furthermore, upregulation of inflammatory markers can be observed in PD patients and 
inflammation (including an activation of microglia and astrocytes) is probably contributing 
to the disease’s progression. Still, inflammation or immune response are most likely not the 
main disease-causing mechanisms (Tufekci et al. 2012). 
At the time the first motor symptoms appear, already 60 - 80 % of the dopaminergic neurons 
in the SNpc have died and even more nigrostriatal projections have been lost – an 
observation which led to the “dying back hypothesis” of a degeneration starting in the distal 
axon (Burke and O'Malley 2013; Tagliaferro and Burke 2016; Dauer and Przedborski 2003). 
Burke and O’Malley proposed that the degeneration of nigrostriatal axons is contributing 
more to the development of PD symptoms than the neuronal loss in the SN. Neurites are 
especially vulnerable to ROS or impaired energy supply and α-synuclein was demonstrated 
to impair cytoskeletal remodeling. Thus, they assumed that better understanding of axon 
growth, their degeneration and regeneration could lead to new therapeutic and possibly 
disease modifying therapies for PD. 
1.1.4 Symptoms and diagnostics of Parkinson’s disease 
1.1.4.1 Clinical symptoms of Parkinson’s disease 
James Parkinson described the originally Paralysis agitans (Shaking Palsy) called disease as an 
“involuntary tremulous motion, with lessened muscular power, in parts not in action [..]; with 
a propensity to bend the trunk forwards” (Parkinson 2002). The rest tremor and the impaired 
gait were the most obvious symptoms. Four cardinal symptoms were identified for what is 
now known as Parkinson’s syndrome: bradykinesia, rest tremor, rigidity and postural and gait 
impairment. Beside these motor symptoms also non-motor symptoms were described which 
were not part of Parkinson’s original description (Massano and Bhatia 2012; Clarke 2007).  
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Bradykinesia describes the reduced pace of the patients in all their actions and their 
disability to rapidly alternate movements (dysdiadochokinesia). Hypomimia (“Poker face”, 
reduced mimic), hypophonia (unclear, soft voice) and micrographia (progressively smaller 
handwriting towards the end of a line) also belong to the summarizing term bradykinesia. 
The predominantly rhythmic 4-6 Hz rest tremor mostly affects relaxed body parts and 
vanishes with active movement (Massano and Bhatia 2012). Although in public perception, 
tremor is the most typical symptom of PD only 48 % of male and 67 % of female patients 
show it. The Parkinsonian rest tremor must not be confused with the essential tremor which 
has a prevalence between 0.4 % and 3.9 % in a general population (Zesiewicz and Kuo 2015). 
The rigidity observed in PD is also described as cogwheel rigidity. In difference to spastic 
palsy the Parkinsonian rigidity is felt throughout the entire movement and does not increase 
(Massano and Bhatia 2012). The “propensity to bend the trunk forwards” observed by 
Parkinson is today described as postural and gait impairment. Patients turn around in 
multiple small steps and fall easily (Jankovic 2015). 
Besides these relatively obvious motor symptoms, PD patients also suffer from several 
neuropsychiatric (e.g. dementia, depression, psychosis, apathy), vegetative (e.g. hyposmia, 
dysphagia, constipation, sexual dysfunction, orthostatic hypotension) and sleep disorders 
(especially rapid eye movement sleep disorders, RBD) as well as pain, fatigue and sensory 
dysfunction. These complaints are important to asses as they can heavily impair the quality 
of life of patients and should also be treated (Massano and Bhatia 2012; Clarke 2007). 
Moreover, these complaints can occur in early stages of the disease even before the onset of 
motor symptoms and are therefore important to monitor when dealing with elderly and other 
risk patients to diagnose PD early (Miller and O'Callaghan 2015; Oertel and Schulz 2016). 
The disease progresses very differently and life expectancy, quality of life or degree of 
disability differ a lot between patients. A better sub-classification of PD is needed for more 
precise prognosis, specific treatment and significant studies. Clinically, three subtypes are 
differentiated according to the leading clinical symptom: an akinetic rigid type, a tremor 
dominant type and an equivalent type. More precise classification systems also include age at 
onset, a larger set of symptoms or biomarkers for differentiation (Thenganatt and Jankovic 
2014; Fereshtehnejad et al. 2015; Eggers et al. 2012). Besides the tremor-dominant 
phenotype, also a benign tremulous PD is described with poor levodopa (L-Dopa) response 
and only mild progression of other PD symptoms. It is therefore discussed to possibly be a 
unique disease (Deeb et al. 2016; Josephs et al. 2006).  
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Moreover, histological differences between clinical PD subtypes were reported. Patients with 
non-tremor dominant PD were described to have significantly more amyloid-β-plaques and 
Lewy bodies in the cortex compared to tremor dominant or early onset PD subtypes 
(Halliday et al. 2011; Selikhova et al. 2009). 
1.1.4.2 Establishing the diagnosis of idiopathic Parkinson’s disease 
The diagnosis of PD follows the criteria of the Movement Disorder Society and starts with 
the identification of a Parkinsonian syndrome consisting of the indispensable bradykinesia 
and at least one out of rest tremor or rigidity. Subsequently, absolute exclusion criteria e.g. 
dealing with reasons of secondary Parkinsonism and aPS related symptoms are ruled out. 
Secondly, at least two supportive criteria such as olfactory loss or improvement after 
dopaminergic therapy shall be identified. Third, red flags such as bilateral symmetric 
symptoms, unusual rapid or slow progression are excluded for the diagnosis of clinically 
established PD. Clinically probable PD can be diagnosed if not more than two red flags are each 
counterbalanced by supportive criteria (Postuma et al. 2015a). 
Thus, the diagnosis relies on the clinical examination and the expertise of the neurologist but 
additional examinations in blood or cerebrospinal fluid (CSF) and general neuroimaging 
techniques can help to exclude other rare causes of the observed symptoms. A hyper-
echogenic substantia nigra in transcranial sonography may support the diagnosis of PD but 
cannot differentiate from atypical Parkinsonism. Single photon emission computed 
tomography (SPECT) of the of presynaptic dopamine transporters (so-called DaTSCAN) 
can help to support the diagnosis especially by differentiating between an essential tremor 
and Parkinson’s disease. Costly but helpful even in the difficult differentiation of PD to some 
aPS, is the Positron-emission tomography with 18fluoro-dopa, 18fluoro-deoxy-glucose 
(18FDG) or 18C-raclopride (Tolosa et al. 2006; Miller and O'Callaghan 2015). 
The course of the disease can clinically be documented with the Hoehn and Yahr scale or 
the Unified Parkinson’s Disease Rating Scale (UPDRS). The neuropathological postmortem 
diagnosis of PD is defined by neuronal loss in the SNpc and Lewy body pathology which 
can be grouped by Braak stages (Dickson et al. 2009).  
Only 75 % to 95 % of the experts’ PD diagnosis are confirmed on autopsy. The accuracy of 
PD diagnosis considerably depends on disease duration and the expert’s experience. Not 
recognizing warning signals for atypical Parkinsonism is one of the main diagnostic errors.   
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Thus, the diagnosis of PD hast to be questioned regularly (Postuma et al. 2015a; Postuma et 
al. 2018). To diagnose PD earlier, proofed by objective parameters and to better differentiate 
PD and aPS, neurologist strive for PD biomarkers. In this context, different metabolites, 
proteins, elements and also miRNAs are investigated in various material such as blood, CSF, 
urine and tear fluid (Stoicea et al. 2016; Miller and O'Callaghan 2015). Even skin biopsies are 
considered for PD diagnosis as phosphorylated-α-synuclein deposits could be found in skin 
nerves of 80 % to 100 % of the examined PD patients but not in healthy controls. 
Interestingly, some patients with RBD – an early symptom of PD – were also positive for 
phosphorylated-α-synuclein (Doppler et al. 2017; Donadio et al. 2014; Postuma et al. 2015b). 
1.1.5 Treatment of Parkinson’s disease 
So far, there is still no disease-modifying therapy available for PD. Instead, symptoms are 
treated by dopamine replacement since the degeneration of nigrostriatal dopaminergic 
projections is the best-understood part in PD pathophysiology. Patients below the age of 70 
are often first treated with a non-ergotamine dopamine agonist such as pramipexol, 
ropinirole or rotigotine. All patients with PD, however, benefit of a treatment with the 
precursor substance levodopa (L-Dopa, 3,4-hydroxyphenylalanin). In contrast to dopamine, 
it crosses the blood-brain barrier and gets then decarboxylated to dopamine. To prevent 
peripheral side effects, L-Dopa is always combined with a peripheral decarboxylase inhibitor 
like benserazide or carbidopa (Bentley and Sharma 2012; Oertel and Schulz 2016). Drugs are 
usually applied orally. For the dopamine agonists, also subcutaneous (apomorphine) or 
transdermal (rotigotine) applications are available. L-Dopa is also available as slow release 
preparation or can be applied as intrajejunal infusion (Duodopa pump) for patients with 
severe motor fluctuations (Oertel and Schulz 2016; Olanow et al. 2014). When fluctuations 
of therapeutic response occur, therapy with L-Dopa or dopamine agonists can be supported 
by inhibiting dopamine degradation using catechol-O-methyl transferase (COMT)-inhibitors 
(entacapone, opicapone, tolcapone) or MAO-B inhibitors (rasagiline, safinamide, selegiline) 
(Oertel and Schulz 2016). Besides, some patients can be helped with deep brain stimulation 
(DBS) of the subthalamic nucleus, globus pallidus pars interna or the ventral intermediate nucleus which 
physiologically inhibit the motoric thalamus. The electric stimulus of the DBS inhibits these 
centers leading to a disinhibition of the motoric thalamus and thereby taking over the effects 
physiologically elicited by dopaminergic nigrostriatal projections. Especially young patients 
with L-Dopa induced motor fluctuations or non-levodopa-responsive tremor can profit 
from DBS (Moldovan et al. 2015; Oertel and Schulz 2016; Herrington et al. 2016).  
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In addition to pharmacological treatment, physical therapy, occupational therapy, speech 
therapy as well as cognitive behavioral therapy are important to maintain patients’ self-
sustainment and social participation (Gage and Storey 2004; Keus et al. 2007). 
Many different strategies have been considered to provide a disease-modifying treatment to 
PD patients. Of course, this research could also benefit enormously from advances in 
biomarker research, better sub-classification of PD types and earlier diagnosis of the disease. 
Future treatment strategies focus on certain parts of the pathogeneses of PD or putative 
protective factors identified in epidemiological studies. It was observed that PD appears less 
frequent in smokers than in non-smokers and even leads to altered MAO-B activity in 
smokers. However, a clinical trial using nicotine as therapy did not slow down disease 
progression and even worsens symptoms compared to placebo control (Oertel et al. 2018). 
The apparent protective effect of smoking can be explained by a lower life expectancy of 
smokers and less addiction potential due to reduced dopamine levels in PD, which makes it 
easier for PD patients to quit smoking (Ritz et al. 2014; Lee and Gilbert 2016; de Lau and 
Breteler 2006). Other factors which are suggested to reduce the risk of developing PD are 
nonsteroidal anti-inflammatory drugs and statins which also have anti-inflammatory 
properties. As drinking coffee is suspected to be a protective factor against developing PD, 
caffeine was also tested for PD treatment but could not improve patients’ motor symptoms 
in a randomized placebo-controlled trial (Postuma et al. 2017). Moreover, high levels of urate 
are suspected to reduce the risk of developing PD. Different safety trials with the urate 
precursor inosine have already shown the safety of the drug and its ability to raise serum and 
CSF levels of urate. Treatment effects of inosine in PD are currently evaluated in clinical 
trials (Schwarzschild et al. 2014; Iwaki et al. 2017; Oertel and Schulz 2016). In the context of 
possible risk and protective factors, it is important to underline, that most of these factors 
were identified retrospectively using questionnaires which are susceptible to recall bias.  
Since a prion like behavior of α-synuclein is discussed, clinical trials try to limit extracellular 
α-synuclein levels to stop further spread through the brain and cell death. Active and passive 
immunotherapies are undergoing clinical phase I or II trials and have not reported any 
serious side effects so far (Oertel and Schulz 2016). Moreover, iron – which is suspected to 
support intracellular α-synuclein aggregation – is also investigated as a putative treatment 
target. In preclinical studies using the A53T mouse model of PD, the iron chelator 
deferiprone and the selective inhibitor of iron-α-synuclein-interaction clioquinol improved 
behavioral deficits (Carboni et al. 2017; Finkelstein et al. 2016). Deferiprone is even tested in 
a large scale clinical trial in patients in early stages of PD (Martin-Bastida et al. 2017).  
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Regarding oxidative stress and mitochondrial dysfunction as a possible part of PD 
pathogenesis, a phase III trial with coenzyme Q10 – a mitochondrial enhancer and 
antioxidant – could not show any benefit for the patients – possibly since the general 
collective of PD patients is still too heterogenous (Beal et al. 2014; Oertel and Schulz 2016). 
Transplantation of human embryonic dopaminergic neurons to patients with severe PD only 
led to an improvement in patients below the age of 60 years (Freed et al. 2001). In another 
similar study, no benefit for the patient was observed but more “off” dyskinesia in treated 
patients (Olanow et al. 2003). Further pharmacological and interventional treatment trials as 
well as basic research are required to identify biomarkers and elucidate pathogenesis of PD 
to provide a better symptom controlling or even disease modifying treatment to PD patients. 
1.2 Epigenetics 
The DNA sequence is the building plan of cells and organisms. However, only ~2 % of the 
DNA fulfill this original building plan hypothesis and encode for proteins (Venter et al. 2001; 
Alexander et al. 2010). Thus, the pure DNA sequence is probably not everything what 
determines the phenotype of an organism. Long before DNA sequences were revealed, 
Conrad Waddington supposed in 1942 that “between genotype and phenotype […] lies a 
whole complex of developmental processes” which he called the “epigenotype” 
(Waddington 2012). 
Epigenetic mechanisms can modify gene expression in different stages. DNA methylation 
or histone modifications alter the transcription of RNA from the DNA template strands by 
regulating the DNA strands’ accessibility for transcription enzymes or factors. This can be 
an important part of cell differentiation but can also be transmitted to following cell or 
organism generations via enzymes copying this epigenetic code during meiosis or mitosis 
(Gibney and Nolan 2010; Riggs and Porter 1996; Bird 2007). Besides, gene expression can 
be modified on a post-transcriptional level during processing of the precursor messenger 
RNA (pre-mRNA) or finally upon translation of the messenger RNA (mRNA). During post-
transcriptional processing, most pre-mRNA transcripts are alternatively spliced, introns are 
removed and (some of) the remaining exons are rearranged. Additionally, high specific base 
exchanges like A-to-I editing or C-to-U-editing increases the variability in protein synthesis. 
In average, 6.3 alternatively spliced transcripts come from one gene locus but one mature 
mRNA only encodes for one protein (ENCODE Project Consortium 2012; Brennicke et al. 
1999).  
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Other RNA transcripts do not encode for protein but control mRNA translation. In 2006, 
Andrew Fire and Craig C. Mello were awarded the Nobel Prize for Medicine and Physiology 
for their description of genetic interference by double stranded RNA (dsRNA). A 
foundation-stone for their research was laid by Lee and colleagues in 1993 who described an 
RNA transcript later called microRNA (miRNA, ~21 to 25 nucleotides) from a non-coding 
gene which specifically regulated the translation of a mRNA by antisense RNA-RNA 
interaction (Fire et al. 1998; Lee et al. 1993). Moreover, small interfering RNA (siRNA, 
~21 to 25 nucleotides) processed by cleavage from exogenous (e.g. viral) or endogenous 
RNA duplexes were described as well as the single stranded Piwi-interacting RNA (piRNA, 
~24-29 nucleotides long). All these three interfering RNAs need to interact with Argonaut 
proteins to bind to their targets. Alterations in their expression regulate gene expression, can 
be acquired and inherited (Siomi and Siomi 2009; Houwing et al. 2007; Heard and 
Martienssen 2014; Benito et al. 2018; Smythies et al. 2014).  
Inheritance of these epigenetic modifications could possibly mean that cells and organisms 
take over the adaptation of their ancestors – one of the key ideas of Jean-Baptiste Lamarck’s 
theory of evolution (1744-1829). Environment induced epigenetic modifications could thus 
influence gene expression, cognitive abilities, disease risks and even fears (Dias and Ressler 
2013; Fischer 2014).  
1.3 miRNA in epigenetic regulation 
miRNAs are a group of non-coding RNA usually between 21 to 25 nucleotides long. They 
are transcribed from DNA mostly by RNA polymerase (RNA Pol) II or III which leads to a 
stem-loop structure – the primary miRNA (pri-miRNA). Many pri-miRNAs are capped at 
their 5’ end and are polyadenylated at the 3’ end just as mRNA. The RNAse III Drosha (also 
called microprocessor complex) together with the dsRNA binding protein DGCR8 then 
cleaves the pri-miRNA which results in an about 65-70 nucleotides long precursor miRNA 
(pre-miRNA). In some cases, a cluster of two to seven pre-miRNA is processed from one 
common pri-miRNA. The transport protein Exportin-5 (XPO5) in complex with Ran-GTP 
then recognizes the pre-miRNA by its hairpin structure and its 3’ overhang and transports 
only correctly processed pre-miRNA into the cytoplasm. In the cytoplasm, the evolutionary 
conserved RNAse III Dicer processes the pre-miRNA into a ~21 to 25 nucleotides long 
duplex RNA with two nucleotides overhang on the 3’ end. Afterwards, the double stranded 
mature miRNA becomes separated, possibly by miRNA specific enzymes.  
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The miRNA strand which has its 5’ end at the site of the thermodynamically less stable base 
pair is selected as the guide strand whereas the passenger strand usually is degraded. Finally, 
the selected guide strand is loaded into the RNA induced silencing complex (RISC). It always 
contains an Argonaute 1 or (more often) Argonaute 2 protein (Ago 1 or 2) and more miRNA 
specific proteins. Dicer and dsRNA unwinding enzymes are suspected to assist in this 
process. The RISC binds especially to the mRNA’s 3’ untranslated region by more or less 
perfect base pairing of the loaded miRNA to the target mRNA. Base pairing is suspected to 
depend especially on the seed sequence between the 2nd and 8th nucleotide of the miRNA’s 
5’ side. However, besides complementary base pairing miRNA targeting probably also 
depends on factors such as miRNA confirmation or accessibility of the target. After pairing 
to its target, RISC can cleave mRNA, inhibit mRNA translation or promote mRNA 
degradation. The exact effect probably differs between species, different miRNA and could 
(among others) depend on the grade of base complementarity (Winter et al. 2009; Siomi and 
Siomi 2009; Ameres and Zamore 2013; Didiano and Hobert 2006; Wang 2014).  
 
Figure 1 Canonical pathway of miRNA biogenesis 
The pri-miRNA is transcribed by RNA polymerase II or III, cleaved to a shorter pre-miRNA by Drosha and 
exported to the cytoplasm via Exportin-5. In the cytoplasm it is cleaved by Dicer, one miRNA strand is selected 
(in this case the red labeled 5’-3’ strand) and is loaded into RISC whereas the other strand is degraded. RISC 
and its loaded miRNA target an mRNA by complementary base pairing and thereby regulate mRNA translation. 
With kind permission of Springer Nature, Winter et al. 2009.   
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Besides this canonical pathway other Drosha and/or Dicer independent pathways are 
described. Intron derived (intragenic) miRNAs can be processed independently of Drosha if 
the initial splicing results in a hairpin RNA with a size like a pre-miRNA. Regarding 
transcription, intragenic miRNAs can both be transcribed and processed with the respective 
gene but also independently controlled by specific promoters (Winter et al. 2009; Wang et al. 
2013b).  
The biogenesis of miRNAs can be regulated at different levels. First, just as gene expression, 
miRNA biogenesis can be regulated by DNA methylation (many miRNAs are located in 
CpG islands) and post-transcriptional modifications of histones. Among others, this alters 
the DNA’s accessibility for a second regulatory mechanism of gene expression – the binding 
of transcription factors to specific promotors. For many miRNAs specific transcription 
factors are described (Wang et al. 2013b). Interestingly, even miRNA which were transcribed 
as a cluster, can be regulated independently (Song and Wang 2008; Magill et al. 2010). Third, 
– just as mRNAs – miRNA can be modified post-transcriptionally, among others by 
deamination of adenosine to inosine (A-to-I-editing). Moreover, several modifications or 
cofactors of miRNA processing enzymes are described to alter the biogenesis of specific 
miRNA (Winter et al. 2009; Wang et al. 2013b). 
1.4 The miRNA cluster 132/212 
1.4.1 Regulation and effects of miR-132/212 
Four miRNA strands are transcribed from the miR-132/212 locus in one common 
pri-miRNA. In humans they are transcribed from an intergenic region on chromosome 17 
p13.3. However, in mice and rats they are transcribed from introns (intragenic regions). Post-
transcriptional editing or processing besides the canonical pathway of miRNA biogenesis is 
described for the miR-132/212 in different species. The mature miR-132-3p and miR-212-
3p share a common seed sequence (5’-AACAGUC-3’) and differ in only five nucleotides. 
Similarity of the sequence and the localization in a common gene locus probably due to 
evolutionary gene duplication. Moreover, both miRNA sequences are highly conserved 
through vertebrates suggesting an essential physiological role (Wanet et al. 2012; Vo et al. 
2005).  
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Figure 2 Structure and sequence of mature and precursor strands from the miR-
132/212 cluster and its evolutionary conservation through different vertebrates 
(A) The mature miRNA strands miR-132-3p and miR-212-3p share a similar sequence. Differences between 
the two miRNAs are highlighted in red. (B) Both mature strands are highly conserved in different vertebrates. 
Differences from the human sequence are highlighted in red. (C) Predicted stem-loop structure and sequence 
of human pre-miR-132 and pre-miR-212. The mature -3p strands are colored in red, the -5p counter strands in 
grey, predicted hydrogen bounds in blue. Modified from Wanet et al. 2012 under the Creative Common 
Attribution Non-Commercial License. 
Transcription of the cluster can be induced by the cAMP-response element binding protein 
(CREB) and the brain-derived neurotrophic factor (BDNF) which are both involved in 
neuronal maturation, differentiation and plasticity. Whereas CREB has several conserved 
binding sites around the miR-132/212 locus, BDNF can induce its transcription indirectly 
via several different pathways. Some of these pathways finally regulate transcription via the 
regulation of CREB but also CREB independent pathways e.g. via ERK1/2 are discussed. 
(Vo et al. 2005; Remenyi et al. 2010). CREB can be a downstream target of BDNF effects 
but BDNF transcription is also directly controlled by CREB. This homeostatic control of 
two miR-132/212 regulating factors becomes more complicated when including the methyl-
CpG-binding protein 2 (MECP2) which is a validated target of both miRNAs.  
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On one hand, MECP2 controls the expression of BDNF, CREB and miR-132/212. On the 
other hand, it is itself a target of miR-132/212 and CREB. These complex mechanisms and 
counter regulations probably ensures a homeostasis of all involved factors which are all 
crucial during maturation and neuron development (Klein et al. 2007; Feng and Nestler 
2010).  
Moreover, the repressor element-1 silencing transcription factor / neuron-restrictive 
silencing factor (REST/NRSF) has a conserved binding site to suppress miR-132/212 
transcription. REST normally suppresses the expression of neuronal proteins in non-
neuronal cells, but it is also present in neurons. During neuronal maturation it is proteolyzed 
and miR-132/212 can be transcribed (Westbrook et al. 2008; Wanet et al. 2012; Zocchi and 
Sassone-Corsi 2012). Interestingly, miR-132-3p was demonstrated to be the mainly expressed 
miRNA from this cluster in primary hippocampal cultures and the dentate gyrus of young 
adult mice (Magill et al. 2010). 
As an epigenetic regulator of gene expression, miRNAs can adapt to the environment and 
miRNAs alterations can even be transmitted to the directly following generation. This was 
demonstrated specifically for the miR-132/212 cluster. Physical exercise and cognitive 
training (environmental enrichment) is known to improve performance in cognitive tasks 
(Fischer 2016). Mice in enriched environment developed increased levels of miR-132/212 in 
hippocampal and sperm specimens. The increased miRNA levels were transmitted to the 
following generation via the male sperm. Although the offspring mice lived in a standard 
environment, they still performed better in cognitive tasks compared to offspring from 
standard environment fathers (Benito et al. 2018). 
Protein regulation by miRNAs affects a high number of targets and even more downstream 
targets. As the sequence of the organism specific miRNAs and its target mRNAs is known, 
algorithms can predict mRNAs targeted by a respected miRNA by complementary base 
pairing and other criteria. Sets of proteins are clustered in pathways according to the Kyoto 
Encyclopedia of Genes and Genomes (KEGG). An analysis of the predicted targets of the 
miR-132/212 seed sequence reveals various significantly affected KEGG pathways involved 
in the regulation of cell growth and cell cycle (Table 1). A respective table of KEGG 
pathways of predicted miR-132/212 targets in mice can be found in Table A1. 
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Table 1 The 15 most significantly affected KEGG pathways in humans according to 
seed-sequence-based target prediction of miR-132/212 targets by targetscan.org 
KEGG pathway Term p-Value 
hsa04350 TGF-beta signaling pathway 3.8E-7 
hsa04360 Axon guidance 6.06E-6 
hsa05200 Pathways in cancer 9.0E-6 
hsa04550 Signaling pathways regulating pluripotency of stem cells 8.2E-5 
hsa05213 Endometrial cancer 1.7E-4 
hsa04068 FoxO signaling pathway 2.4E-4 
hsa04010 MAPK signaling pathway 6.7E-4 
hsa04728 Dopaminergic synapse 6.8E-4 
hsa05215 Prostate cancer 8.8E-4 
hsa04663 B cell receptor signaling pathway 9.6E-4 
hsa04022 cGMP-PKG signaling pathway 9.7E-4 
hsa04917 Prolactin signaling pathway 1.1E-3 
hsa05202 Transcriptional misregulation in cancer 1.5E-3 
hsa04151 PI3K-Akt signaling pathway 2.3E-3 
hsa04510 Focal adhesion 3.0E-2 
The mature miR-132-3p strand is the best investigated strand from the miR-132/212 cluster 
– probably because miR-212 was discovered much later. The affected KEGG pathways of 
miR-132/212 include among others Axon guidance and Pi3K-Akt signaling pathway which fits 
well to numerous studies reporting augmented neurite outgrowth and spine density in various 
models with increased levels of miR-132-3p (Vo et al. 2005; Pathania et al. 2012; Magill et al. 
2010; Impey et al. 2010; Hansen et al. 2010; Wayman et al. 2008). It was also reported that 
mild elevations of miR-132-3p levels improve performance in cognitive animal tests whereas 
knockout of the miR-132/212 locus worsens learning and spatial memory. In this context, 
the observation was explained by the miRNAs’ ability to regulate neuronal plasticity and long 
term potentiation – possibly via their target MECP2 (Hansen et al. 2016; Hansen et al. 2013; 
Benito et al. 2018; Hernandez-Rapp et al. 2015; Aten et al. 2016). Moreover, a small RNA 
sequencing comparing primary midbrain neuronal (PMN) cultures between the first and fifth 
day in vitro (DIV) identified a massive increase in miR-132-3p and miR-212-3p expression at 
the later time point suggesting an essential role of these miRNAs in neuronal maturation 
(Roser 2016; Roser et al. 2018b). These observations suggested a further investigation of the 
miRNA cluster in disease contexts as growth and maturation-associated mechanisms are also 
suspected to be involved in regeneration. 
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1.4.2 miR-132/212 in disease and as therapeutic target 
Pathways involved in growth or maturation – such as many of the KEGG pathways in Table 
1 – are frequently also involved in cancer. One of the major suppressors of miR-132/212 
transcription, REST, was observed to be downregulated in different types of cancer 
(Westbrook et al. 2008). Thus, alterations of miR-132/212 were described among others in 
pancreatic, gastric or lung cancer. Interestingly, the direction of miRNA regulation differed 
between studies. Although, some studies could demonstrate cancer suppressing effects of 
increased miR-132/212 levels, it cannot be said for sure whether the miRNA alteration is 
causal for cancer development, a reaction to or a consequence of it (Zhang et al. 2011; Park 
et al. 2011; Luo et al. 2014; Wada et al. 2010; Wanet et al. 2012).  
Besides, the miR-132/212 is intensively investigated in cardiovascular diseases. As miR-
132/212 targets the pro-autophagic transcription factor FOXO3, increased miR-132/212 
levels are associated with the development of cardiac hypertrophy. Inhibition of miR-132-
3p with antagomir (specific synthetic oligonucleotides against miRNA) could prevent cardiac 
hypertrophy and heart failure in mice (Ucar et al. 2012; Thum et al. 2013).  
To diagnose diseases early and to estimate patients’ prognosis, miRNA from different body 
fluids were also investigated as putative biomarkers in various diseases. For instance, the low 
serum levels of miR-132 and miR-212 correlate with poor survival in patients with 
hepatocellular carcinoma (Wang et al. 2018a) but in patients with acute myeloid leukemia 
high miR-212 expression is associated with a prolonged survival (Sun et al. 2013).  
Furthermore, miRNAs were investigated as putative biomarkers for PD as the diagnosis is 
still mainly based on clinical criteria and differential diagnosis to aPS is challenging. Different 
body fluids such as saliva, CSF, blood and different fractions of it (CSF exosomes, whole 
blood, serum, blood cells) were investigated. Among the repeatedly reported miRNAs are 
miR-1-3p, miR-19b-3p, miR-29a-3p, miR-29c-3p, miR-214-3p, miR-221-3p. The majority of 
them were downregulated in PD (Roser et al. 2018a). Single miRNA could differentiate PD 
from healthy controls with an area under the curve (AUC) between 0.92 for miR-1-3p 
(downregulated) to 0.97 for miR-409-3 (upregulated) under the receiver operating 
characteristic (ROC) curve. Combined measurement of miR-153 and miR-409-3p in 
exosomes from CSF even led to an AUC of 0.99 (Gui et al. 2015). For miR-132/212 
biomarker reports are contradictory. Some reports could not even detect miR-132-3p in their 
CSF samples (Marques et al. 2017). One study reported an upregulation of miR-132-5p in 
CSF exosomes (Gui et al. 2015), whereas another study showed a downregulation of miR-
132-5p in post mortem CSF (Burgos et al. 2014).  
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More multicentric studies with larger cohorts, comparable specimens and techniques are 
needed to further evaluate miRNAs as putative biomarkers in PD. 
miRNAs are also investigated as putative therapeutic targets. In a model of Huntington’s 
disease (HD) both miR-132 strands were found to be decreased. Subsequently, after 
transduction of miR-132 with an adeno-associated virus (AAV), motor function improved, 
and lifespan expanded. Interestingly, the disease-causing Huntingtin (HTT) gene products 
were not changed. The authors discussed interactions of MECP2 and its binding to BDNF 
as a possible mechanistic background (Fukuoka et al. 2018; McFarland et al. 2014). In the 
R6/2 mouse model of HD miR-132-3p, miR-212-5p and miR-212-3p were found decreased 
and transduction with miR-132-3p overexpressing virus could even improve survival and 
motor symptoms (Fukuoka et al. 2018). Since the influence of miR-132/212 on 
neuroplasticity and learning was frequently described, they were also investigated in the 
context of AD. The knockdown of the miR-132/212 locus was found to impair learning, 
memory and tau metabolism – the pathological hallmark of AD (Smith et al. 2015; Leggio et 
al. 2017). In AD patients miR-132-3p was found downregulated and high miR-132/212 
levels correlated with better cognitive scores which was associated with miR-132/212 
induced downregulation of Sirtuin 1 (SIRT1) (Hadar et al. 2018). Another study observed an 
upregulation of miR-132/212 after acute and chronic stress in hippocampus or amygdala. 
Both, genetic overexpression and knockout of miR-132 increased anxiety-like behaviors 
(Aten et al. 2018). 
In the context of PD, miR-132-3p directly targets the nuclear receptor related protein 1 
(NURR1) and thereby inhibits the differentiation into mature dopaminergic neurons. As 
NURR1 regulates BDNF which in turn regulates miR-132, they jointly ensure their 
homeostasis (Yang et al. 2012; Lau et al. 2013; Heman-Ackah et al. 2013; Leggio et al. 2017). 
Mutations in NURR1 are also associated with familial Parkinsonism. It was reported to be 
downregulated in α-synuclein rich dopaminergic midbrain neurons of PD patients and 
deletion of NURR1 led to a progressive PD-like pathology. It is thus discussed as a putative 
target in PD treatment (Grimes et al. 2006; Lou and Liao 2012; Decressac et al. 2012; 
Decressac et al. 2013). In this specific context, PD patients would rather benefit from low 
levels of miR-132 to ensure stable levels of NURR1 whereas patients with other ND profit 
from increased miR-132 levels.  
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Several patents were already issued regarding therapeutic miRNAs (Chakraborty et al. 2017; 
Hesse and Arenz 2014). However, miRNAs are not yet approved as a therapeutic agent or 
medical target. Clinical trials are running for inhibitors and mimics of miRNAs in the 
treatment of scleroderma and different neoplasia. Two inhibitors of miR-122 against 
Hepatitis C even completed phase II trials (Rupaimoole and Slack 2017). Moreover, the 
discovery of non-coding RNAs led to the approval of the siRNA Patisiran for a rare type of 
hereditary polyneuropathy and various antisense oligonucleotides targeting diseases specific 
targets. Nusinersen (Spinraza) for patients with spinal muscle atrophy, eteplirsen (Exondys 
51) in Duchenne muscle dystrophy and mipomersen (Kynamro) in homozygous familial 
hypocholesterolemia are the pioneers in this new field of therapeutic agents. More clinical 
trials are running for ALS targeting SOD1 and HD targeting HTT but not yet for PD – the 
second most common ND after AD (Khorkova and Wahlestedt 2017; Scoto et al. 2018; 
Hanna et al. 2019).  
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1.5 Aim of  this study 
Neuroscientific reports repeatedly reported beneficial effects of miR-132/212 expression for 
cognition and learning. Moreover, the miRNA cluster was investigated in various models of 
neurodegenerative diseases like HD, AD and also PD. In cell culture models of cortical, 
hippocampal, neuroblastoma and cell line neurons or embryonic stem cells molecular 
mechanisms were investigated and several targets of the miRNA cluster were identified 
(Hansen et al. 2016; Sun et al. 2018; Yang et al. 2012; Wanet et al. 2012). Single miRNA from 
the cluster were already explored in PD models (Fukuoka et al. 2018). However, their targets 
and mechanisms in dopaminergic midbrain neurons have not yet been investigated even 
though the degeneration of these neurons is an important part of PD pathophysiology. Most 
studies exclusively investigated effects of miR-132-3p but did not analyze other miRNA from 
the cluster nor combinations of them although they are transcribed together from a common 
gene locus. An upregulation of miR-132-3p and miR-212-3p was reported upon maturation 
in PMN. As mechanisms of neuronal maturation and growth are probably also relevant for 
neuronal regeneration, it is interesting to further investigate the effects of these miRNAs in 
these processes (Roser et al. 2018b).  
This study aims to investigate the effects of increased levels of the mature strands miR-132-
3p and miR-212-3p in PMN and in vitro models of PD. To increase miRNA levels, PMN are 
transfected with synthetic miRNA mimics. In a second step, the underlying mechanisms of 
miR-132-3p- or miR-212-3p-mediated effects are investigated. In contrast to most other 
studies, experiments are performed for both mature miRNAs to compare their effects. 
Moreover, a combined condition with increased levels of both miRNAs is included. Based 
on the observed effects and identified mechanisms the therapeutic potential of the two 
miRNAs is evaluated. 
First, an optimal concentration for the transfection with synthetic miRNA mimics had to be 
found. Subsequently, the influence of increased miR-132-3p or miR-212-3p levels on neurite 
outgrowth in dopaminergic PMN was analyzed. To investigate possible effects on 
neuroregeneration and neuroprotection a mechanical and a toxic degeneration model were 
used. For an unbiased investigation of protein alterations induced by increased levels of the 
miRNA, the PMN’s proteome was assessed by liquid chromatography with tandem mass 
spectrometry (LC/MS/MS) for an identification and quantification of its proteins 
(proteomics). Analysis of the proteome can both help to identify new targets but also to 
reveal indirect or downstream effects of the transfected miRNA. Selected proteins from 
literature and proteomics analysis were also investigated by immunoblotting.  




Table 2 Table of reagents used for experiments 
Reagent Producer Purpose 
1-bromo-3-chloropropane Sigma Aldrich (Germany) RNA isolation from PMN 
1-methyl-4-phenylpyridinium 
(MPP+) 
Sigma Aldrich (Germany) PD in vitro model in PMN 
2-propanol AppliChem (Germany) 




Sigma Aldrich (Germany) Nuclear co-staining for ICC 
Acrylamide AppliChem (Germany) 
Gel preparation for SDS-
PAGE 
Ammonium chloride (NH4Cl) Merck (Germany) Fixation for staining 
Ammonium persulfate (APS) Sigma Aldrich (Germany) 
Gel polymerization for SDS-
PAGE 
B-27 Supplement Gibco (Germany) 
Supplement for cell culture 
medium 
Bovine serum albumin (BSA, 
2mg/ml) 
AppliChem (Germany) 
BCA measurement of 
protein concentration 
Bromophenol blue Sigma Aldrich (Germany) Stacking gel 
cOmplete Protease Inhibitor Sigma Aldrich (Germany) Laemmli buffer supplement 
DAKO antibody diluent DAKO (Germany) Staining solutions for ICC 
DNAse Sigma Aldrich (Germany) Cell culture processing 
Fetal calf serum (FCS) Biochrom (Germany) Cell culture processing 
Glycoblue Coprecipitant Thermo Fisher Scientific (USA) RNA isolation 
Hank’s Balanced Salt Solution 
(HBSS) 
Gibco (Germany) CMF for cell culture 
Laminin Sigma Aldrich (Germany) Well/ coverslip coating 
L-Ascrobic acid (L-AA) Sigma Aldrich (Germany) Cell culture medium 
L-Glutamine 200mM (100x) Gibco (Germany) Cell culture medium 
Methanol AppliChem (Germany) 
Transfer buffer for Western 
blot 
Mowiol Sigma Aldrich (Germany) Mounting of coverslips 
Neurobasal A medium Gibco (Germany) Cell culture medium 
Non-fat dried milk AppliChem (Germany) 
Blocking and antibody 
dilution for Western blot 
Paraformaldehyde (PFA)  AppliChem (Germany) Fixation for staining 
Phosphate buffered saline 
(PBS) 
AppliChem (Germany) Washing of samples 
PhosStop Roche (Germany) Laemmli buffer supplement 
Pierce BCA Assay  
Reagent A + B 
Thermo Fisher Scientific (USA) 
Measurement of protein 
concentration 
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Reagent Producer Purpose 
Poly-L-ornithine (PLO) Sigma Aldrich (Germany) 
Coating of cell culture wells 
or coverslips 
Precision Plus Protein Dual 
Color 
Bio-Rad (Germany) 
Protein size reference in 
during Western blot 
Radioimmunoprecipitation 
(RIPA) buffer 
Thermo Fisher Scientific (USA) Cell lysis 
RNAse free (DEPC treated) 
water 
Sigma Aldrich (Germany) Dilution of RNA or DNA 




Gel Polymerization for 
SDS-PAGE 
Tris HCl AppliChem (Germany) 
Preparing TBS for Western 
blot 
TritonX 100 AppliChem (Germany) 
Permeabilization for ICC 
staining 
Trizol (TRI Reagent) Sigma Aldrich (Germany) Cell lysis for RNA isolation 
Trypsin Biochrom (Germany) Processing tissue for PMN 
Tween 20 AppliChem (Germany) 
Washing detergent for 
Western blot 
2.2 Primers, miRNA mimics and kits 
Table 3 Table of primers, miRNA mimics, their sequences and kits used for 
experiments 
Kit / Sequence Producer Purpose 
AllStars Negative Control siRNA (20nM) Qiagen (Germany) Transfection of PMN 




HiPerfect transfection reagent Qiagen (Germany) Transfection of PMN 
Hs_RNU6-2_11 miScript Primer Assay Qiagen (Germany) qPCR 
miScript II RT Kit Qiagen Qiagen (Germany) Reverse Transcription 
miScript SYBR Green PCR Kit Qiagen (Germany) qPCR 
Mm_miR-212 miScript Primer Assay Qiagen (Germany) qPCR 
Syn-mmu-miR-129-2-3p  
(AAGCCCUUACCCCAAAAAGCAU-3p) 
Qiagen (Germany) Transfection of PMN 
Syn-mmu-miR-132-3p 
(UAACAGUCUACAGCCAUGGUCG-3p) 
Qiagen (Germany) Transfection of PMN 
Syn-mmu-miR-212-3p  
(UAACAGUCUCCAGUCACGGCCA-3p) 
Qiagen (Germany) Transfection of PMN 
Syn-mmu-miR-7b-5p 
(UGGAAGACUUGUGAUUUUGUUGUU-5p) 
Qiagen (Germany) Transfection of PMN 
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2.3 Antibodies 
Table 4 Table of antibodies and their dilution used for immunocytochemistry 
Primary Antibodies Producer Dilution 
Anti-tyrosine hydroxylase (anti-TH) – 
polyclonal, anti-rabbit 
Zytomed (Germany) 
1:1000 in DAKO 
antibody diluent 
Secondary Antibodies Producer Dilution 
Goat IgG anti-rabbit IgG, Cy3 conjugated 
Cell Signaling (United 
Kingdom) 
1:250 in DAKO 
antibody diluent 
Table 5 Table of antibodies and their dilutions used for immunoblotting 
Primary Antibodies Producer Dilution 
Anti-EPHA5 – polyclonal, 
rabbit 
LSBio (USA) 




HyTest Ltd (Finland) 




Cell Signaling Technology (USA) 




Cell Signaling Technology (USA) 









Dr. Takanobu Nakazawa, Institute of Medical 
Science, University of Tokyo, Tokyo, Japan 
(Nakazawa et al. 2003) 
1:800 in 2.5 % 
milk-TBS-T 
Secondary Antibodies Producer Dilution 
Anti-mouse IgG, HRP 
linked Antibody 
Cell Signaling Technology (USA) 




Cell Signaling Technology (USA) 
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2.4 Solutions and buffers 
Table 6 Table of solutions and buffers used for experiments 
Solution Composition Purpose 
Blocking solution for 
Western blot 
5 % non-fat dried milk in TBS-T 
Prevents unspecific 
binding in Western blot 
experiments 
Borate buffer boric acid buffered with NaOH to pH 8.4 Dilution of PLO 
Calcium-magnesium-
free medium (CMF) 
10 % HBSS diluted in distilled water, pH 
adjusted with ~ sodium bicarbonate 
PMN preparation and 
cell processing 
Cell culture medium 
2 % B27-supplement, 1 % glutamine,  
0.1 % 200mM L-AA in Neurobasal 
PMN cell culture 
DAPI solution 1 μg/ ml DAPI in PBS Nuclear staining for ICC 
Laemmli buffer 
312.5 mM Tris pH 6.8, 10 % SDS, 50 % 
Glycerin, 0.005 % Bromophenol blue,  
100 mM DTT 




0.1 % TritonX 100 in PBS 
Permeabilization of cells 
for ICC 
Tris 10 mM Tris-buffered saline pH 8.0 
Dilution of reagents for 
Western blot 
Tris buffered saline 
(TBS) 
10 mM Tris HCl, 150 mM NaCl in 
distilled water 
Dilution of reagents for 
Western blot 
Tris buffered saline 
with Tween20 (TBS-T) 
0.1 % Tween20 in TBS, pH 7.6 
Dilution of reagents for 
Western blot 
2.5 Composition of  gels for SDS-PAGE 
Table 7 Composition of gels for SDS-PAGE 
Compounds 8 % gel  14 % gel  Stacking gel  
30% acrylamide 2.27 ml 3.97 ml 0.325 ml 
4x Tris Cl/SDS pH 8.8 2.13 ml 2.13 ml ---- 
4x Tris Cl/SDS pH 6.8 --- --- 0.625 ml 
water (distilled) 4.11 ml 2.41 ml 1.515 ml 
10% APS 42.5 µl 42.5 µl 12.5 µl 
TEMED 4.25 µl 4.25 µl 2.5 µl 
0.5% Bromophenol blue  --- --- 10 µl 
(Composition for two gels) 
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2.6 Equipment 
Table 8 Table of equipment used for experiments 
Equipment Producer Purpose 
12 well cell culture plates  Sarstedt (Germany) 
PMN culture for RNA 
isolation 
24 well cell culture plates 
CytoOne 
USA Scientific (USA) PMN culture for ICC 
6 well cell culture plates Cellstar Greiner bio-one (Austria) 
PMN culture for protein 
isolation 
96 well micro test plates Sarstedt (Germany) 
BCA measurement of 
protein concentration 
96 well microamp Endura Plate Thermo Fisher Scientific (USA) qPCR 
Cover slides 76 x 26 mm Menzel (Germany) PMN culture for ICC 
EV 2310 power supply  Consort (Belgium) 
Power supply for 




Vilber Lourmat (Germany) Western blot Imaging 
Mastercylcer nexus X2 Eppendorf (Germany Reverse Transcription 
Micro-centrifuge 5415R Eppendorf (Germany) Cell culture Processing 
Mini-Protean Tetra-Cell system Bio-Rad (Germany) 
Western blot and SDS 
PAGE 
NanoDrop One Thermo Fisher Scientific (USA) 
Measuring RNA 
concentration and purity 
Polyvinylidene fluoride (PVDF) 
immunoblotting membrane 
GE Healthcare (United 
Kingdom) 
Western blot 
Quant Studio 3 Thermo Fisher Scientific (USA) 
q-RT-PCR machine 
control 
RNAse -Exitus Plus AppliChem (Germany) 
Cleaning before RNA 
work 
Spacer plates / short plates Bio-Rad (Germany) 
Preparing gels for SDS-
Page 
Tecan Spark 10M plate reader Tecan (Switzerland) 
BCA measurement of 
protein concentration 
Thermomixer Comfort Eppendorf (Germany) 
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2.7 Software 
Table 9 Table of software used for experiments, data analysis and figure design 
Equipment Producer Purpose 
AxioVision 4.6 Software Carl Zeiss (Germany) Microscope control 
CorelDraw X6 16.1.0.843 
 Graphics Suite 
Corel Corporation (Canada) Figure design 
Evolution Capt 17.03 Vilber Lourmat, (Germany) Imaging of 
immunoblots and 
image analysis 
GraphPad Prism 5.04 GraphPad software (USA) Graph design and 
statistical analysis 
ImageJ 1.51 National Institute of Health (USA) Neurite tracing and 
somata counting 
KyPlot 5.0 KyensLab (Japan) Statistical analysis 
Neuron J Plugin 1.4.3 Erik Meijering (Netherlands) Neurite tracing 
Perseus 1.5.6.0 Computational Systems Biochemistry, 
Max Planck Institute, Martinsried 
Germany (Tyanova et al. 2016) 
LC/MS/MS SWATH 
data evaluation 
Venny 2.1 (Web tool) Juan Carlos Oliveros, Centro Nacional 
de Biotechnologia (Spain) 
Overlap analysis for 
proteomics data 
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3 Methods 
3.1 Primary midbrain neuronal cultures 
3.1.1 Experimental animals 
Pregnant C57Bl6/J mice were used as donor animals for primary cell culture preparation. 
They were provided by the central animal facility of the University Medical Center of 
Göttingen. The mice were kept in standard multiple housing in 12 hours dark/light cycle and 
were fed ad libitum. At the embryonic day 12.5 shortly before preparation, they were 
euthanized using carbon dioxide (CO2) and death was confirmed by testing the mice’s toe 
pain reflexes. All experiments are in line with the national German animal protection law and 
were approved by the local authorities (project name: T10/28 Embryonenentnahme). 
3.1.2 Coating the coverslips and culture plates 
To provide suitable growing conditions for the PMN cultures, wells were coated with poly-
L-ornithine (PLO) dissolved in borate buffer and diluted with sterile water to a final 
concentration of 0.1 mg/ml incubating overnight at room temperature (RT). Subsequently, 
wells were coated with laminin (0.1 µg/ml) diluted in neurobasal medium (Gibco, Germany) 
without supplements, incubated for one hour at 37°C / 5 % CO2 and stored at 4°C. For 
immunocytochemistry (ICC) cleaned and sterilized glass coverslips (Ø 12 mm) were placed 
into wells of a 24 well-plate and coated as described above. Shortly before preparation, the 
laminin solution was removed, wells were washed three times with neurobasal medium (free 
of supplements) and the required amount of supplemented neurobasal medium (2 % B27,  
1 % glutamine, 0.1 % 200 mM L-ascorbic acid (L-AA)) was filled in every well (Table 10). 
3.1.3 Preparation of primary midbrain neurons 
The euthanized, pregnant mice were disinfected with 70 % ethanol and skinned using two 
small Overholt forceps. Afterwards the peritoneum was opened, and the uterus was worked 
free from ligaments, vessels and the vagina. Embryos were then removed from their amniotic 
sacs and kept in ice-cold calcium-magnesium-free medium (CMF). Subsequently, the 
midbrain vesicle was dissected and opened longitudinally on its dorsal part. Meninges were 
removed and the ventral part of the midbrain vesicle containing the dopaminergic neurons 
was dissected and kept in ice-cold CMF. Cells were centrifuged at 1000 rounds per minute 
(equal to 86 x g relative centrifugal force (rcf)) for 1 min, CMF was removed, and the tissue 
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was kept for 12 minutes in a 37°C water bath with 0.25 % trypsin for tissue digestion. 
Afterwards, 50 µl DNAse (5 mg/ml) was added and the cell suspension was again centrifuged 
at 1000 rounds per minute (rpm) / 86 x g rcf for 1 min. Trypsin was removed, and fetal calf 
serum (FCS) was added to inactivate trypsin. To achieve a single cell suspension, the solution 
was triturated with a very narrow, fire polished Pasteur pipette. After a final centrifugation 
at 1000 rpm / 86 x g rcf for 4 min, CMF was removed, and the cells were resuspended in 
supplemented pre-warmed neurobasal medium. Concentration of healthy cells was 
quantified using a Neubauer chamber and plated accordingly as displayed in Table 10. The 
cell cultures were then kept in a humidified incubator at 37°C and 5 % CO2. If the cells were 
kept until DIV 4, half of the wells total medium was changed at DIV 3. This protocol for 
PMN cell culture was established earlier in the same lab and was shown to contain on average 
~ 6 % dopaminergic neurons, 94 % gamma-aminobutyric acid (GABA) transmitting neurons 
and only single cells positive for glial fibrillary acid protein (GFAP) (Lingor et al. 1999). 
Table 10 Number of cells and amount of medium for different cell culture plates and 
experiments 
Wells per plate Number of cells 
Final amount of 
medium  
Purpose 
6 wells 3 x 106 2400 µl Preparation for protein isolation 
12 wells 1.5 x 106 1200 µl Preparation for RNA isolation 
24 wells 650.000 600 µl Preparation for ICC experiments 
3.2 Transfection of  PMN cultures with miRNA mimics 
Cell cultures were always transfected at DIV 1, 24 hours after plating the cells. The 
transfection solution was based on supplemented cell culture medium, complemented with 
2 µl HiPerfect transfection reagent (Qiagen, Germany) per 100 µl transfection solution and 
the respective miRNA mimics (Qiagen, Germany). The miRNA mimics are transfected as 
double stranded synthetic RNA, being only one strand biologically active according to the 
manufacturer. AllStars Negative Control siRNA (Qiagen, Germany) – a validated negative 
control which has no homology to any mammalian gene known – was used as negative 
control (NC). The amount of miRNA mimics respectively NC siRNA was calculated for 
concentrations of 0.5 nM, 5 nM or 50 nM for the corresponding final volume of the well 
depending on the plate format (Table 10). Before adding to the plates, the transfection 
solution was vortexed for 1 min and left undisturbed for 10 min at RT to allow formation of 
transfection complexes. Three hours after transfection, half of the culture media was 
removed from the wells and replaced with prewarmed supplemented cell culture medium. 
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3.3 Measuring miRNA levels for transfection amount study 
To find a suitable amount for the transfection of PMN with miRNA mimics three different 
concentrations of 0.5 nM, 5 nM and 50 nM were tested. All RNA work was performed under 
laminar air flow after cleaning thoroughly with RNAseZAP. Earlier studies from the lab 
demonstrated that the transfection protocol successfully transfects 84 ± 1.0 % of all PMN 
cells (Roser et al. 2018b). For the miR-132-3p the transfection efficacy and dose findings 
experiments were performed by L. Caldi Gomes in a previous project using the same 
protocol (Caldi Gomes 2016). 
3.3.1 RNA Isolation from PMN cultures 
Total RNA was isolated from PMN at DIV 3. At first, all the media was removed, and cells 
were washed once with cold phosphate buffered saline (PBS). Afterwards, cells were lysed with  
1 ml Trizol reagent (Sigma Aldrich, Germany) per well incubating for 5 min at RT. The lysate 
was pipetted up and down several times and transferred to an Eppendorf tube. For phase 
separation, 100 µl of 1-bromo-3-chlor-propane were added to each tube, mixed thoroughly 
and kept undisturbed for 5 min at RT. After 15 min centrifugation with 12.000 x g rcf at  
4°C, the upper – RNA containing – layer was carefully transferred to another Eppendorf 
tube, without entering or disturbing the other layers. For RNA precipitation, 500 µl 
isopropanol were added together with 1.5 µl Glycoblue (Thermo Fisher Scientific, USA) to 
stain the RNA pellet and cells were kept overnight at -20°C. The next day, samples were 
centrifuged for 30 min at 12.000 x g rcf at 4°C. Isopropanol was removed and the blue 
colored RNA pellet was washed two times with cold 75 % ethanol – carefully watching not 
to break the pellet. In between two washing steps, samples were centrifuged 5 min at 12.000 
x g rcf at 4°C, before the ethanol was removed again. After removing the ethanol, the second 
time, pellets were air dried for 12 min and then diluted in 10 to 15 µl RNAse free water. 
Finally, samples were incubated 5 min at 55°C (Thermomix comfort, Eppendorf, Germany), 
to completely dissolve all RNA. Afterwards, samples were stored at -20°C. 
3.3.2 RNA and DNA quantification 
To measure the total concentration of the isolated RNA and to exclude possible 
contaminations with extraction liquids or proteins, 1 µl of the RNA sample was pipetted into 
the measuring unit of the Nano Drop One device (Thermo Fisher Scientific). After the 
reverse transcription the concentration of the complementary DNA (cDNA) was also 
measured with the Nano Drop One device.   
3 Methods 32 
 
3.3.3 Reverse transcription 
In a first step, RNA had to be converted into cDNA. The concentration measured in the 
NanoDrop One was used to dilute 500 ng RNA in 6 µl RNAse free water. A Master Mix 
was prepared as shown in Table 11 containing miScript HiSpec Buffer, Nucleics Mix and 
Reverse Transcriptase (all Qiagen, Germany). All pipetting was done under RNAse free 
conditions. Afterwards, everything incubated in the Mastercylcer nexus X2 (Eppendorf, 
Germany) at 37°C for 60 minutes, followed by 5 minutes at 95°C to inactivate the enzyme. 
The concentration of the produced cDNA was also measured using the NanoDrop One 
device. Subsequently, samples were stored at -20°C.  
Table 11 Master Mix contaminants for reverse transcription 
Component Volume per reaction 
500 ng Sample RNA diluted in 6 µl RNase-free water 6 µl 
5x miScript HiSpec Buffer 2 µl 
10x miScript Nucleics Mix 1 µl 
miScript Reverse Transcriptase 1 µl 
Total 10 µl per reaction 
3.3.4 Quantitative real time polymerase chain reaction 
The amount of cDNA gained from the isolated RNA after reverse transcription was assessed 
by quantitative real-time polymerase chain reaction (q-RT-PCR) using the QuantStudio 3 q-
RT-PCR machine (Thermo Fisher Scientific, USA). The small nuclear RNA U6-2 gene 
(RNU6-2) was selected as housekeeping control gene. First, a Master Mix was prepared for 
every target gene as displayed in Table 12. 
Table 12 Master Mix contaminants for qPCR 
Components Volume per reaction 
2x QuantiTect SYBR Green PCR Master Mix 7.5 µl 
10x miScript Universal Primer 1.5 µl 
10x miScript Specific Primer (RNU6-2 or miR-212) 1.5 µl 
RNAse-free water 3.0 µl 
Total Volume Master Mix per reaction 13.5 µl  
Afterwards, 1.5 µl of the sample cDNA was pipetted to the wells on a 96-well-plate, followed 
by 13.5 µl Master Mix. All experimental conditions (three different concentrations of miRNA 
mimics, NC siRNA and the respective corresponding RNU-6 control) were measured in 
duplicates on the same plate. The plate was sealed and centrifuged 2 min at 1000 rpm / 86 x 
g rcf and loaded into the RT-PCR machine. The qPCR settings are displayed in Table 13. 
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Table 13 Cycle length and temperature for qPCR 
Step Time Temperature 
PCR initial activation step 15 min 95°C 
3-step cycling 
     Denaturation 15 s 94°C 
     Annealing 30 s 55°C 
     Extension 30 s 70°C 
Number of cycles 40 cycles 
The q-RT-PCR measurements were only taken into consideration as long as two blank 
samples of each Master Mix with 1.5 µl of the used water did not show any contamination. 
The delta-delta cycle threshold method (ΔΔCt method) was used to quantify the expression 
data of the mRNA. The Ct values of miRNA were first normalized to the RNU6-2 Ct values 
from the same sample and subsequently to the experimental NC siRNA transfected cells. 
3.4 Neurodegeneration models in vitro 
In order to investigate the influence of the experimental conditions on neuroprotection, 
neurodegeneration and regeneration of dopaminergic PMN, two cell stress models were 
used. 
3.4.1 Scratch lesion model 
To simulate a mechanical damage model, cultures were scratched twice in an X-shape with a 
sterile 200 µl pipette at DIV 2. As in all experiments for ICC, the cultures were fixated at 
DIV 4, followed by ICC staining and imaging. For this experiment, two cultures treated with 
5 nM miR-132-3p were prepared, stained and imaged by L. Caldi Gomes following the same 
protocol as described here. The subsequent evaluation was performed together with all other 
conditions. 
3.4.2 1-Methyl-4-phenylpyridinium (MPP+) treatment 
Stress resistance and neuroprotective abilities were investigated using MPP+ which 
specifically targets dopaminergic neurons through catecholaminergic transporters. Within 
the cell, MPP+ can generate free radicals, disturb calcium homeostasis, axonal transport and 
inhibit mitochondrial complex I. This can lead to insufficient energy supply and induction 
of apoptosis (Kopin 1992).  
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Cell survival was investigated in PMN on 24 well-plates with coverslips. The MPP+ treatment 
was applied at DIV 2 at a final concentration of 2 µM per well, diluted in prewarmed 
supplemented cell culture medium. As vehicle control, duplicates of every experimental 
condition were treated with prewarmed, supplemented cell culture media instead of MPP+. 
The whole medium of all wells was removed and replaced with prewarmed supplemented 
neurobasal medium to avoid augmented toxicity 24 hours later. Cells were fixated at DIV 4 
and prepared for immunocytochemistry. For this experiment, three 5 nM miR-132-3p treated 
PMN cultures, were prepared, MPP+ treated, stained and imaged by L. Caldi Gomes 
following the same protocol. The subsequent evaluation was performed together with all 
other conditions. 
3.5 Immunocytochemistry  
The influence of the transfected miRNA mimics on neurite growth or regeneration of 
dopaminergic PMN was evaluated using immunocytochemistry. 
3.5.1 Fixation, staining and preparation for immunocytochemistry of PMN 
Cells for ICC were always fixated at DIV 4 using 350 µl of 4 % paraformaldehyde (PFA) per 
well incubating for 20 min at RT. Afterwards, PFA was removed and 350 µl of 200 mM 
ammonium chloride (NH4Cl) were added incubating 10 min followed by three times washing 
for 5 min with PBS. If staining was not performed the same day, cells were stored sufficiently 
covered with PBS at 4°C. For permeabilization, cells were incubated 10 min with PBS-T 
(PBS with 0.1 % Triton) and blocked with DAKO antibody diluent for 20 minutes. A 
primary rabbit antibody against tyrosine hydroxylase (TH, Zytomed) was used to selectively 
stain dopaminergic neurons. For this purpose, the primary antibody was diluted 1:1000 in 
DAKO antibody diluent and incubated for 1 h at 37°C with 180 µl per well. After three more 
times washing with PBS for 5 min, a secondary Cy3 conjugated goat anti-rabbit antibody, 
diluted 1:250 was applied incubating 30 min at 37°C. Once more, cells were washed three 
times for 5 min with PBS and 200 µl of 4’,6-diamidino-2-phenylindole (DAPI) (1 µg/ml in 
PBS) was applied for 5 min for a nuclear co-staining. After washing the cells three more 
times for 5 min with PBS, coverslips were mounted on glass slides using prewarmed Mowiol. 
If not described differently all incubation and washing steps were performed on a shaker at 
RT, protected from light.  
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3.5.2 Immunocytochemistry imaging  
The coverslips were imaged at 20x magnification using the Axioplan 2 imaging microscope 
(Zeiss, Germany) together with the corresponding AxioVision 40 software (Version 4.8.2.0). 
For evaluation of neurite growth and MPP+ survival, four by four mosaic images were taken 
at prior defined spots 2500 µm towards the center from three, six, nine and twelve o’clock 
sides of the coverslips. For the scratch lesion experiment, four by six mosaic images were 
taken along the scratch border. During one experiment all microscope and software settings 
were always kept unchanged. 
3.5.3 Evaluation of immunocytochemistry photomicrographs 
To evaluate the neurite growth of dopaminergic PMN, all TH positive neurites detectable in 
the Cy3 channel were quantified using the Neuron J Plugin of the Image J software (version 
1.4.3). Subsequently, the total number of TH positive somata was counted with Image J 
(version 1.51) and an average neurite length per soma was calculated. In the scratch lesion 
experiment, only the length of regenerating TH positive neurites from the scratch border to 
the neurite tip was measured. Afterwards, the sum of the length of the seven longest neurites 
in each picture was calculated for normalization. For the evaluation of neuroprotective 
effects of the miRNA mimics in the MPP+ model, TH positive cell somata were counted and 
divided by the numbers in the medium treated vehicle control of the same condition. During 
one experiment, the defined scale and magnification were always kept the same. All images 
were analyzed at the same monitor in a darkened room. 
3.6 Proteome analysis of  miRNA transfected PMN 
To identify proteins regulated by the transfected miRNA mimics, proteins were isolated from 
PMN and subjected to mass spectrometry for a first and unbiased screening. Selected 
proteins were then further evaluated using Western blot. 
3.6.1 Preparation of cell lysates from PMN 
Cell lysates were always prepared at DIV 3. To reduce cell metabolism, all steps were 
performed on ice and with cold reagents. First, media was removed, and dead cells were 
washed out with PBS. Subsequently, 100 µl radioimmunoprecipitation assay (RIPA) buffer 
(Thermo Fisher Scientific, USA) supplemented with phosphatase inhibitor 1:20 and 
complete proteasome inhibitor 1:20 were given to every well and incubated 10 min on ice. 
Subsequently, cells were scraped off using a cell scraper and transferred to Eppendorf tubes. 
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Afterwards, all samples were sonicated two times for 15 s at an amplitude of 40 % resulting 
in an additional mechanical cell lysis. Samples were kept on ice between sonication cycles to 
avoid protein denaturation. 
3.6.2 Protein quantification and processing of cell lysates 
To prepare samples with equal protein concentrations for further experiments, the protein 
concentration was measured with the Pierce bicinchoninic acid Assay (Pierce BCA Assay, 
Thermo Fisher Scientific, USA). Triplicates of 1 µl per sample diluted in 199 µl BCA reagent 
(Reagent B: Reagent A, 1:50) were compared to an eight well standard curve. The standard 
curve had 20 µg of bovine serum albumin (BSA 2 mg/ml, AppliChem, Germany) in its first 
well, subsequently diluted 1:2 to the next wells (BSA per well: 20 µg, 10 µg, 5 µg, 2.5 µg,  
1.25 µg, 0.625 µg, 0.313 µg, 0.156 µg) and filled up to 200 µl BCA solution per well. All 
samples and standard curve wells were run in triplicates and incubated for 30 min at 37°C. 
Finally, absorbance was measured at 562 nm using the Tecan Spark 10M plate reader (Tecan, 
Switzerland) and concentration was calculated relatively to the standard curve. Subsequently, 
a solution of the required protein concentration diluted in Laemmli buffer with 10 % 
dithiothreitol (DTT) was prepared and incubated 5 min at 95°C before storing at -80°C. 
3.6.3 LC/MS/MS on PMN protein lysates 
For every experimental condition three replicates per condition á 50 µg in 30 µl Laemmli 
buffer with 10 % DTT were prepared as described above. The following protein analysis by 
LC/MS/MS was performed by the proteomics facility led by Dr. Christof Lenz and Prof. 
Dr. Henning Urlaub, Institute of Clinical Chemistry, University Medical Center Göttingen 
who kindly provided the following protocol. The material used for the LC/MS/MS is not 
listed in the material chapter of this thesis. 
In a first step, sodium dodecyl sulfate (SDS) was removed by running 50 µg of each sample 
on 4-12 % NuPAGE Novex Bis-Tris Minigels (Invitrogen, USA) for 1.5 cm. The protein 
bands were stained using Coomassie, cut out, treated with DTT for reduction, iodacetamide 
for alkylation and finally with trypsin overnight for in-gel digestion. After the solution had 
dried in a Speedvac, samples were stored at -20°C (Atanassov and Urlaub 2013).  
Library preparation was performed from a pool of all samples (total amount: 80 µg) after 
separation into eight fractions using a reversed phase spin column (Pierce High pH Reversed-
Phase Peptide Fractionation Kit, Thermo Fisher Scientific, USA). A synthetic peptide 
standard was used for retention time alignment (iRT standard, Biognosys, Switzerland). 
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Prior to the mass spectrometry run, peptides were dissolved to a concentration of 0.3 µg/µl 
in loading buffer (2 % acetonitrile, 0.1 % formic acid in water). On a precolumn (0.18 mm 
ID x 20 mm, Symmetry C18, 5 µm, Waters, USA) 1.5 µg digested protein were enriched for 
each analysis and separated on an analytical RP-C18 column (0.075 mm ID x 250 mm, HSS 
T3, 1.8 µm, Waters, USA) using a 90 min linear gradient of 5-35 % acetonitrile/0.1 % formic 
acid at 300 nl min-1. Finally, protein digests were than conducted to a nanoflow 
chromatography system (Eksigent nanoLC425) hyphenated to a hybrid triple quadrupole-
TOF mass spectrometer (TripleTOF 5600+) equipped with a Nanospray III ion source 
(Ionspray Voltage 2400 V, Interface Heater Temperature 150°C, Sheath Gas Setting 12) 
under control of Analyst TF 1.7.1 (all AB Sciex, USA).  
A Top25 data-dependent acquisition method was used for qualitative LC/MS/MS analysis. 
The total cycle time was 2.9 s with an MS survey scan of m/z 350 - 1250 for 350 ms at a 
resolution of 30,000 full width at half maximum (FWHM) and following MS/MS scans of 
m/z 180 - 1600 for 100 ms at 17,500 FWHM. The precursor isolation width was 0.7 FWHM.  
Only precursors with charge states of 2+, 3+, and 4+ with an MS intensity of at least  
125 counts per second were selected for MS/MS. The MS/MS run was started by collision 
induced dissociation with nitrogen as a collision gas at the manufacturer’s default rolling 
collision energy settings with a dynamic exclusion time of 30 s. For one reversed phase 
fraction four technical replicates were analyzed to construct a spectral library. 
In 65 variable size windows between 400 - 1,050 m/z range MS/MS data were acquired for 
data independent quantitative sequential windowed acquisition of all theoretical fragment ion 
mass spectra (SWATH-MS) analysis (Zhang et al. 2015). Rolling collision energy settings for 
charge state 2+ were used for fragmentation. A 100 ms survey scan and fragment acquisition 
for 40 ms per segment at an m/z range of 350 - 1400 led to an overall cycle time of 2.75 s. 
For protein identification, the total MS/MS spectra from the combined qualitative analysis 
was compared against 52 laboratory contaminants and the UniProtKB Mus musculus reference 
proteome (revision 12-2017, 60,769 entries) using the ProteinPilot software version 5.0 (AB 
Sciex, USA) at “thorough” settings. Retention time was corrected by the iRT standard and 
linked to the MS/MS library at F (FDR) of 1%.  
Subsequently, the spectral library was generated, and SWATH-peaks extracted using the 
SWATH quantitation microAPP (version 2.0) of the PeakView software (version 2.1, AB 
Sciex, USA). Only proteins detected in every run and sample were taken into consideration 
for quantification (Lambert et al. 2013; Losensky et al. 2017). Peak areas were summed to 
peptide, and finally protein area values.  
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3.6.4 Interpretation of SWATH-MS data and miRNA target prediction 
For statistical analysis data were imported to Perseus 1.5.6.0 software, quantitative values 
were log2 transformed to achieve a normal data distribution and Perseus’ Significance B 
analysis was performed (Cox and Mann 2008; Tyanova et al. 2016). Subsequently, the 
significantly regulated proteins were imported to the Database for Annotation Visualization, 
and Integrated Discovery (DAVID, version 6.8) for KEGG pathway and gene ontology 
(GO) analysis (Huang et al. 2007; Huang et al. 2009).  
In order to identify predicted targets among the regulated proteins in SWATH-MS, target 
prediction was performed with three different target prediction algorithms – targetscan.org 
(Agarwal et al. 2015), microrna.org (Betel et al. 2010; Betel et al. 2008) and mirwalk.org 
(Dweep and Gretz 2015). Whereas microrna.org and mirwalk.org differentiate between miR-
132-3p and miR-212-3p, tragetscan.org predicts targets only based on the seed sequence 
which is the same for miR-132-3p and miR-212-3p. Comparative analysis of predicted targets 
and proteins measured in SWATH MS was performed with Venny 2.1.0 (Oliveros 2007). 
3.6.5 Western blot 
In a first step of cell lysate analysis, proteins were separated by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). The anionic SDS contained in the Laemmli buffer covers the 
amino acids of proteins so that all proteins become similarly negatively charged and are only 
separated according to their size and molecular weight. Furthermore, the gels basic pH of 
8.8 reduces positive protein charges. According to the BCA measurements, stock solutions 
of 1.25 µg/µl in Laemmli Buffer with 10 % DTT were prepared for every sample. The 
electrophoresis was run with 25 µg per sample. For band identification 4 µl marker (Precision 
Plus Protein Dual Color, Bio-Rad, Germany) were used. Electrophoresis was run in a Mini-
Protean Tetra-Cell system (Bio-Rad, Germany) until the running had reached the bottom of 
the gel.  
Subsequently to the SDS-PAGE, the separated proteins were transferred to a polyvinylidene 
fluoride (PVDF) membrane (GE Healthcare, United Kingdome). First, the PVDF 
membrane was incubated in pure methanol for 30 s and then packed in the same system as 
used for electrophoresis. The proteins were transferred in transfer buffer containing 10 % 
methanol at constant voltage and 4°C. Afterwards, the membrane was incubated in 5 % non-
fat dried milk (AppliChem, Germany) diluted in tris buffered saline with Tween20 (TBS-T) 
followed by the incubation with the required primary antibody overnight at 4°C.  
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Afterwards, the membrane was washed three times with TBS-T for 10 minutes and an 
appropriate secondary antibody incubated one hour at RT on the shaker followed by three 
more times washing with TBS-T for 10 minutes.  
For three proteins the SDS-PAGE was run on 8 % gels at 40 V for 4.5 hours followed by 
16 hours transfer at 30 V using the following antibodies: anti-ROCK2 (Rho associated 
coiled-coil containing protein kinase 2) rabbit antibody (1:1000 in 5 % BSA in TBS-T), anti-
EPHA5 (EPH-Receptor A5) rabbit antibody (1:1000 in 5 % milk in TBS-T, LS Bio, USA), 
anti-ARHGAP32 (Rho GTPases activating protein 32) rabbit-antiserum (1:800 in 2.5 % milk 
in TBS-T by Takanobu Nakazawa, Tokyo, Japan (Nakazawa et al. 2003)). Two more proteins 
were investigated on 14 % gels with an electrophoresis at 80 V for 2.5 hours, followed by 
two hours transfer at 100 V with the following antibodies: anti-MECP2 monoclonal rabbit 
antibody (1:1000 in 5% BSA in TBS-T, Cell signaling technology, UK), anti-TAX1BP3 (Tax1 
binding protein 3) monoclonal rabbit antibody (1:1500, in 5 % BSA in TBST-T, Abcam, 
UK). The gel composition can be found in the material chapter (Table 7). In all experiments, 
GAPDH was used as loading control (1:5000 in 2.5 % milk in TBS-T, HyTest Ltd, Finland). 
As secondary antibodies, horseradish-peroxidase (HRP)-linked anti-rabbit IgG (1:1000 in 5 
% milk in TBS-T, Cell signaling, UK) and anti-mouse IgG (1:2000 in 2.5 % milk in TBS-T, 
Cell signaling, UK) were used. 
Finally, the blot was imaged using the Fusion Pulse Chemiluminescence Imager (Vilber, 
Germany) with ECL Prime Western blotting Detection Reagent (GE Healthcare, United 
Kingdom) controlled by the EvolutionCapt 17.03 software. Also, the image analysis was 
performed with the named software. 
3.7 Statistical analysis 
KyPlot v2.0 (KyensLab) and Prism v5.04 (GraphPad software) were used for statistical 
analysis and graph design. Data were tested for normal distribution using the Shapiro-Wilk 
test and are given as mean or median ± standard error of the mean (SEM, always given with 
the figure description). A pair-wise comparison of normally distributed date was performed 
with a one-way analysis of variance (ANOVA) followed by Tukey’s test for the interpretation 
of qPCR data. All other experiments compared more than one experimental condition to 
NC. Therefore, a one-way ANOVA followed by Dunnett’s test was used for normally 
distributed data whereas the Kruskal Wallis followed by Dunn’s test was applied for not 
normally distributed data. Sample size, specific tests and statistical details are given with the 
respective figures. Differences were considered significant if p <0.05 (* p<0.05, ** p<0.01).   
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4 Results 
4.1 Transfection of  PMN with different doses of  miRNA mimics 
To test the transfection protocol and find an appropriate transfection concentration for the 
selected miRNA, PMN were transfected with final well concentrations of 0.5 nM, 5 nM or 
50 nM double stranded syn-mmu-miR-132-3p respectively syn-mmu-miR-212-3p mimics. 
As a negative control, cells were transfected with 5 nM NC siRNA. RNA was isolated, 
transcribed to cDNA and miRNA levels were measured by qRT-PCR (Figure 3).  
 
Figure 3 Transfection of PMN with miRNA mimics 
(A) Experimental plan for testing transfection with different miRNA mimic concentrations. After transfection 
with different concentrations of miRNA mimics or NC at DIV 1, RNA was isolated at DIV 2 (24 h post-
transfection). (B/C) Expression levels of miR-132-3p (B; experiment conducted by L. Caldi Gomes, (Caldi 
Gomes 2016)) and miR-212-3p (C) after transfection with synthetic miRNA mimics at 0.5 nM, 5 nM and 50 
nM final well concentration. RNU6 expression was used as endogenous control. Data were analyzed with the 
ΔΔCT method and are shown as mean ± SEM expressed in log2 fold change (fc, both n = 4). Data were 
analyzed by one-way ANOVA followed by pair-wise comparison using Tukey’s post-hoc test and are given as 
mean ± SEM. * p < 0.05 
Figure 3 shows the miR-132-3p (B) and miR-212-3p (C) levels after transfection with the 
indicated concentrations of miRNA mimics relative to endogenous expression levels in NC 
transfected cells as analyzed by the ΔΔCT method. Both miRNAs show increased expression 
levels indicating that the miRNA mimics successfully transfected the cells. The miRNA levels 
measured by qRT-PCR also increased with increasing transfection concentrations showing a 
clear dose-dependent effect. The levels of miR-132-3p increased to 3.02 log2 fc for the  
0.5 nM concentration and reached a plateau with an increase of 6.85 log2 fc for the 5 nM 
respectively 7.00 log2 fc for the 50 nM concentration. Both, the 5 nM and the 50 nM 
concentration of miR-132-3p mimics led to significantly higher levels in qPCR compared to 
the 0.5 nM condition.  
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For miR-212-3p expression increased to 3.60 log2 fc for 0.5 nM, to 5.40 log2 fc for 5 nM and 
to 7.70 log2 fc for the 50 nM transfection concentration. Here, only the miRNA levels 
between the 0.5 nM and the 50 nM concentration of miR-212-3p mimics were significantly 
different. To compare the effects of the two miRNA mimics in the following experiments, 
5 nM was selected as suitable transfection concentration. 
4.2 Increased levels of  miR-132-3p enhanced neurite growth in 
dopaminergic PMN 
To evaluate the influence of increased levels of miRNA-132-3p and miRNA-212-3p in 
dopaminergic PMN, cells were plated on coverslips, transfected with 5 nM miRNA mimics 
at DIV 1 (Figure 4-A) and fixated for analysis at DIV 4. Staining against TH was used to 
exclusively label dopaminergic neurons and look for possible alterations in only this specific 
type of neurons. The total neurite length per TH positive cell was quantified relatively to the 
respective NC transfected cells of the same culture and is displayed in Figure 4-B.  
 
Figure 4 Elevated miR-132-3p levels increase neurite length in dopaminergic PMN 
(A) Experimental scheme for the investigation of neurite length after transfection with 5 nM miRNA mimics 
at DIV 1 (1/2 MC = half of the wells’ medium changed). (B) Quantification of the total neurite length per TH 
positive cell in different experimental conditions normalized to NC siRNA transfected cultures (miR-132 n = 
6, miR-212 n = 10, miR-132+212 n = 9). (C) Representative micrographs of TH positive PMN of all 
experimental conditions as indicated (scale bar 50 µm). Data were analyzed by one-way ANOVA with 
Dunnett’s post-hoc test and are given as mean ± SEM. ** p<0.01. 
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Transfection with 5 nM miR-132-3p mimics led to a significant increase of neurite outgrowth 
in dopaminergic PMN by 24.0 ± 2.0 % SEM (p = 0.0034). On the other hand, neither the 
transfection with miR-212-3p (101.4 ± 3.6 % SEM, p = 0.98) nor the combined transfection 
with both miRNAs (110.0 ± 1.1 % SEM, p = 0.25) altered neurite outgrowth (Figure 4-B). 
Interestingly, the combined transfection of both miRNAs diminished the beneficial effect of 
miR-132-3p on neurite outgrowth of dopaminergic PMN.  
4.3 Elevated levels of  miR-132-3p improve regeneration of  
dopaminergic neurites after scratch lesion 
On DIV 1, PMN were transfected with 5 nM miRNA mimics or NC siRNA. Neurites were 
transected by a scratch lesion at DIV 2 (Figure 5-A). After fixation at DIV 4 and 
immunostaining against TH, the length of regenerating dopaminergic neurites crossing the 
scratch border was measured.  
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Figure 5 Only miR-132-3p improves regeneration after scratch lesion in 
dopaminergic PMN 
(A) Experimental plan to investigate the neurite regeneration of TH positive neurons after scratch lesion. Cells 
were transfected at DIV 1, neurites transected at DIV 2 and fixated at DIV 4. (B) Relative neurite length of the 
seven longest neurites per image normalized to NC siRNA transfected PMN (miR-132 n = 5, miR-212 n = 9, 
miR-132+212 n = 10). (C) Exemplary brightfield (bottom) and fluorescent (TH immunostained and DAPI 
counter stained) (top) micrographs of transfected PMN with a dotted line indicating the scratch border 
(conditions as indicated; scale bar 50 µm). Data were analyzed by one-way ANOVA with Dunnett’s test and 
are given as mean ± SEM. * p < 0.05 
The results displayed in Figure 5 show that transfection with 5 nM miR-132-3p mimics 
significantly increases neurite regeneration by 20.0 % ± 1.8 % SEM compared to NC siRNA 
treated cells (p = 0.046, n = 5). Transfection with miR-212-3p (101.5 % ± 4.0 % SEM,  
p = 0.9921, n = 9) or miR-132-3p+212-3p (102.9 % ± 3.6 % SEM, p = 0.95, n = 10) did 
not alter neurite regeneration of TH positive neurons relative to NC siRNA transfected 
cultures (Figure 5-B).  
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4.4 Neither miR-132-3p nor miR-212-3p mimics have neuroprotective 
effects in MPP+ treated dopaminergic PMN 
In order to investigate a possible beneficial effect of higher levels of miR-132-3p and  
miR-212-3p on the survival of dopaminergic neurons, the catecholaminergic neurotoxin 
MPP+ was used which leads to specific degeneration of dopaminergic neurons. Cells were 
transfected with 5 nM miRNA mimics at DIV 1 and 2 µM MPP+ were applied at DIV 2 for 
24 hours. Supplemented cell culture media was used as a vehicle control. At DIV 3, the whole 
cell culture media was changed both for the treated and the vehicle control wells (Figure 6-
A). After fixation at DIV4 and staining against TH, the number of TH positive somata was 
counted. The results are displayed in Figure 6. 
 
Figure 6 Survival of MPP+ treated dopaminergic PMN is not altered by increased 
levels of miR-132-3p or miR-212-3p 
(A) Experimental layout to investigate survival of TH positive neurons after 2 µM MPP+ treatment. (B) Relative 
number of surviving TH positive cells in MPP+ treated cultures, normalized to vehicle control (cell culture 
medium) treated PMN (miR-132-3p n = 3, miR-212-3p n = 6, miR-132-3p+212-3p n = 6). (C) Representative 
micrographs of TH immunostained MPP+ treated (top row) and vehicle treated PMN (bottom row, scale bar 
200 µm). Data were analyzed by one-way ANOVA with Dunnett’s test and are given as mean ± SEM. 
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Treatment with 2 µM MPP+ led to a stable decrease of TH positive neurons by ~50 % in all 
experimental conditions. Neither transfection with miR-132-3p nor with miR-212-3p mimics 
altered the survival of dopaminergic neurons after MPP+ treatment. In NC siRNA treated 
wells, the number of TH positive cells was decreased to 48.6 % ± 0.7 % SEM (n = 10) 
compared to the cell culture medium treated vehicle control. For miR-132-3p transfected 
PMN, number of TH positive neurons was reduced to 45.7 % ± 3.9 % SEM (n = 3) and to 
53.8 % ± 1.0 % SEM (n = 6) for miR-212-3p transfected PMN. The combined transfection 
of both miRNAs did not increase survival either (55.5 % ± 1.3 % SEM, Figure 6-B). 
Compared to NC siRNA transfected PMN the survival rate of TH positive neurons was not 
changed by none of the conditions.  
4.5 miR-7b-5p and miR-129-2-3p do not alter neurite growth, neurite 
regeneration or survival of  dopaminergic PMN 
miR-7b-5p and miR-129-2-3p were also among the most regulated miRNA in the small RNA 
sequencing comparing the miRNAome of PMN at DIV 1 and DIV 5. Following the same 
hypothesis, that miRNA involved in maturation and growth could also act beneficial on 
dopaminergic neurons, the influence of increased miR-7b-5p and miR-129-2-3p levels was 
investigated under the same conditions as for the miR-132-3p and miR-212-3p (Figure 7).  
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Figure 7 miR-7b-5p and miR-129-2-3p do not alter neurite growth, neurite 
regeneration after scratch lesion or survival of dopaminergic neurons after MPP+ 
treatment in dopaminergic PMN 
(A) Experimental layout for neurite growth analysis. (B) Relative neurite length per TH positive cell in miR-7b-
5p and miR-129-2-3p transfected PMN normalized to NC siRNA treated cultures (both n = 4). (C) 
Representative micrographs of TH immunostained transfected PMN cultures (conditions as indicated; scale 
bar 50 µm).  
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[Legend of Figure 7] (D) Experiment layout to investigate neurite regeneration after scratch lesion. (E) 
Quantification of regenerating TH positive neurites after scratch lesion relative to NC (both  
n = 3). (F) Representative micrographs of TH immunostained and DAPI counter stained PMN with a dotted 
line indicating the scratch border (transfection conditions as indicated; scale bar 50 µm). (G) Experimental 
layout to investigate survival of dopaminergic PMN after treatment with 2 µM MPP+. (H) Quantification of 
surviving TH positive neurons after MPP+ treatment relative to vehicle treated control cultures (miR-7b-5p  
n = 6, miR-129-2-3p n = 5). (I) Representative micrographs of TH positive neurons treated with MPP+ (top 
row) or vehicle (bottom row; conditions as indicated; scale bar 200 µM). Data were analyzed by one-way 
ANOVA with Dunnett’s test and are given as mean ± SEM. 
Although the miR-7b-5p and miR-129-2-3p were also upregulated upon maturation, they did 
not alter neurite length of dopaminergic neurons. Dopaminergic PMN transfected with miR-
7b-5p showed a neurite length of 100.6 % ± 14.7 % SEM (n = 4, p = 0.69) and  
miR-129-2-3p showed 90.1% ± 8.0 % SEM (n = 4, p = 0.33) compared to NC siRNA 
transfected cells (Figure 7 B). The two miRNAs did not alter regeneration of dopaminergic 
neurites after scratch lesion either. Compared to NC siRNA transfected PMN, the relative 
length of regenerating dopaminergic neurites was 93.9 % ± 4.0 % SEM (n = 3, p = 0.947) 
for miR-7b-5 and 78.5 % ± 9.7 % SEM (n = 3, p = 0.84) in miR-129-2-3p transfected 
dopaminergic PMN. 
After treatment with 2 µM MPP+ the number of TH positive neurons in NC siRNA treated 
PMN was reduced to 48.6 % ± 0.7 % SEM (n = 10) compared with the vehicle control. In 
the miR-7b-5p transfected condition 56.4 % ± 2.3 % SEM (n = 6, p = 0.20) and  
45.6 % ± 2.6 % SEM (n = 5, p = 0.72) of the miR129-2-3p transfected cells survived 
compared to the respective vehicle control. The two miRNAs did not show any neuro 
protective properties after MPP+ treatment either. The survival rate of none of the conditions 
was significantly different from NC siRNA transfected PMN (Figure 7 H). 
4.6 LC/MS/MS proteome analysis of  miR-132-3p and miR-212-3p 
transfected PMN 
miRNA regulate gene expression by inhibition of mRNA translation and are thus affecting 
protein levels. In order to identify differentially regulated proteins after transfection with 
miR-132-3p or miR-212-3p mimics that might be relevant to the observed effects in the cell 
culture experiment, LC/MS/MS proteome analysis was employed. Cells were transfected 
with 5 nM miRNA mimics respectively NC siRNA at DIV 1 and lysed at DIV 3 (Figure 8-
A). Three samples of 50 µg protein in a final volume of 30 µl were prepared from every 
culture.  
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A total of 4,349 proteins were identified at an FDR of 1 % by mapping the measured 623,867 
MS/MS spectra to the UniProtKB Mus musculus reference proteome. After retention time 
correction to an iRT standard, 3,311 proteins could be quantified. The statistical analysis of 
differential protein expression was performed with the Significance B analysis of the Max 
Quant Perseus software (version 1.5.6.0).  
 
Figure 8 Proteome expression in miR-132-3p and miR-212-3p transfected PMN 
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[Legend of Figure 8] (A) Experimental layout for the investigation of protein expression using mass 
spectrometry. (B) The Venny diagram shows the overlap of differentially expressed proteins after transfection 
with miR-132-3p respectively miR-212-3p with predicted targets for their common seed sequence 
(targetscan.org). The part of the predicted targets also quantified in SWATH-MS is visualized as yellow circle 
within the lower circle of all predicted targets. The absolute numbers in an overlap of two or more circles means 
that this number of proteins matched to the criteria of more than one circle. In contrast, numbers enclosed by 
only one circle were found exclusively in the respective group. The total number of proteins in one group 
consist of the sum of all numbers enclosed by the respective circle. The percentages refer to the sum of all 
proteins from all four circles. (C/D) Differentially expressed proteins in SWATH-MS for miR-132-3p (C) and 
miR-212-3p (D) are depicted in a scatter plot. Less abundant proteins are found to the left, more abundant 
proteins to the right. The color of the dots reflects the significance according to the Significance B analysis of 
Perseus 1.5.6.0. Significantly different expressed proteins are displayed with larger diamonds in contrast to the 
smaller and not filled circles of not significantly regulated proteins. Proteins also investigated in Western Blot 
are named and highlighted. (E/F) The ten most up (blue) or down (red) regulated proteins for miR-132-3p (E) 
and miR-212-3p (F) are given as median log2fc (n = 3). The protein TAX1BP3 is highlighted in red, as it was 
further evaluated in Western Blot. 
In the miR-132-3p treated cells 101 proteins (3.1 % of all quantified proteins) were 
differentially expressed whereas only 83 proteins (2.5 %) were significantly altered in miR-
212-3p transfected PMN compared to treatment with NC siRNA. Eleven proteins were 
similarly upregulated, and 24 proteins downregulated in both treatment conditions. This is 
an overlap in protein regulation of 38 % between the two miRNAs mimics transfected 
conditions. Opposite protein regulation with an upregulation in one and a downregulation 
in the other treatment condition was not observed. Out of 414 predicted targets only 111 
(26.8 %) could be identified and quantified in the present SWATH-MS (yellow-circle in 
Figure 8-B). 
The regulated proteins were mapped to the seed sequence-based target prediction by 
targetscan.org. The overlap of predicted targets and proteins regulated differentially in at 
least one condition in SWATH-MS is depicted in Figure 8-B and includes the following six 
proteins: PAPOLA and ARHGEF11 are the only proteins predicted for both and 
significantly downregulated by both miRNAs (overlap of all three circles). The overlap of 
predicted targets and proteins regulated in miR-132-3p transfected PMN included RRAS2, 
MECP2 and MAPT. While RRAS2 and MECP2 were downregulated, surprisingly, MAPT 
was upregulated. Since miRNA regulate gene expression by translational inhibition resulting 
in decreased protein expression, the upregulation of MAPT cannot be a direct effect of  
miR-132-3p but rather a downstream effect of the miRNA’s targets. The same goes for the 
predicted target SRSF1 which was upregulated by miR-212-3p.  
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Other databases with different prediction algorithms identified 16 (microrna.org) or 67 
(mirwalk.org) regulated proteins to be also predicted targets of miR-132-3p and 17 
(microrna.org) or 65 (mirwalk.org) for miR-212-3p. An overview of proteins both regulated 
and predicted by the three different databases can be found in Table A2 in the appendix.  
The significantly regulated proteins were imported to DAVID to identify involved KEGG 
pathways and GO clusters. DAVID revealed “Huntington’s disease” (mmu05016), 
“Alzheimer’s disease” (mmu05010) and “Tight junction” (mmu04530) to be significantly 
affected in the miR-132-3p transfected cells. The pathways and their regulated targets from 
SWATH-MS are displayed in Table 14. For miR-212-3p, no KEGG pathways were 
significantly involved. 
Table 14 Significantly regulated KEGG pathways and corresponding differentially 





Tight junction (mmu04530) 



















Furthermore, an analysis of the GO clusters of the differentially regulated proteins was 
performed with DAVID. The analysis revealed 13 regulated GO clusters for miR-132-3p 
and 7 for miR-212-3p mimic transfected PMN lysates and are displayed in Table A3 in the 
appendix. 
Three significantly involved GO clusters of miR-132-3p targets and the respective proteins 
are given exemplary in Table 15. The GO clusters “Rho protein signal transduction” 
(GO:0007266), “Synapse assembly” (GO:0007416) and “Nervous system development” 
(GO:0007399) included among others MECP2 and ARHGEF11 which were already 
identified as predicted targets of miR-132-3p and miR-212-3p. Besides, these clusters are 
related to the growth-related questions addressed in the ICC experiments. 
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Table 15 Significantly involved GO cluster and corresponding differentially expressed 




Rho protein signal 
transduction (GO:0007266) 
Nervous system development 
(GO:0007399) 













4.7 Analysis of  protein expression in miR-132-3p and miR-212-3p 
treated PMN by Western blot 
After the SWATH-MS proteomics already indicated several interesting proteins regulated by 
increased miR-132/212 levels and thus possibly relevant for the mediation of the observed 
neurobiological effects, the proteomics results had to be validated by another method. 
Besides already validated targets like MECP2 and ARHGAP32, three regulated proteins from 
SWATH-MS were selected exemplary for validation by Western blot – namely ROCK2, 
TAX1BP3 and EPHA5. These proteins were already reported earlier to be involved in 
regulation of neurite growth but not yet validated as targets of the miR-132/212 cluster. Out 
of these three proteins, levels of TAX1BP3 were increased in both conditions, whereas 
ROCK2 was exclusively downregulated in the miR-132-3p samples and EPHA5 only in miR-
212-3p treated cells. The two proteins regulated exclusively in one condition were further 
investigated, to uncover underlying mechanism possibly explaining the different effects 
observed in ICC: To investigate the expression of the named proteins after transfection with 
one of the two miRNA mimics, PMN were transfected at DIV 1 and lysed at DIV 3 using 
RIPA buffer (Figure 9-A). Western blot analysis was performed with 25 µg protein per gel 
pocket. GAPDH was used as a housekeeping reference and protein levels are shown relative 
to levels in NC siRNA transfected cells.  
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Figure 9 Expression of selected proteins of miR-132-3p or miR-212-3p transfected 
PMN in Western blot 
(A) Experimental layout to investigate protein expression. (B-D) The Western blot analysis for (B) MECP2 (n 
= 10), (C) ARHGAP32 (n = 10), (D) TAX1BP3 (n = 9), (E) ROCK2 (n = 12) and (F) EPHA5 (n = 10).  
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[Legend of Figure 9] Data were first normalized to the loading control GAPDH and subsequently to the NC 
of the respective culture. Exemplary blot images of the loading control and the respective protein are shown 
below the graphs. Data were analyzed by one-way ANOVA with Dunnett’s test and are given as mean ± SEM, 
with exception of ARHGAP32. For this protein data were not distributed normaly (Shapiro -Wilk Test p = 
0.027) and were analyzed by the Kruskal Wallis and Dunn’s test. * p<0.05, ** p< 0.01.  
MECP2 is a predicted and validated target of both miRNAs and is also described to be 
involved in neuronal plasticity and morphogenesis. Indeed, its downregulation is reported to 
increase neurite length (Klein et al. 2007; Wada et al. 2010; Alvarez-Saavedra et al. 2011; Im 
et al. 2010; Bhattacherjee et al. 2017). In Western blot, MECP2 was found downregulated to 
71.2 % ± 7.8 % SEM (p = 0.045) for miR-132-3p but not changed significantly for miR-212-
3p (89.1 % ± 12.6 % SEM (p = 0.57 both n = 10, Dunnett’s test, Figure 9-B). In SWATH 
MS, it was also only found downregulated for miR-132-3p (-0.38 median log2 fc).  
The ARHGAP32 protein is also known under the no longer recommend term p250GAP. It 
was already shown to be regulated by miR-132-3p and to mediate neurite growth in other 
models (Vo et al. 2005; Magill et al. 2010). However, it was not expressed significantly 
different in the proteomics experiment (miR-132-3p: -0.47 median log2 fc). In Western blot, 
miR-132-3p transfected PMN had 20.7 % ± 3.4 % SEM (p = 0.001) decreased expression 
of ARHGAP32 whereas protein expression was not changed for miR-212-3p transfected 
PMN (97.2 % ± 14.1 %, p = 0.632, both n = 12, Kruskal Wallis and Dunn’s test, 
Figure 9-C).  
TAX1BP3 was significantly upregulated in SWATH-MS for both miRNAs (miR-132-3p: 
1.85 median log2fc, miR-212-3p: 1.61 median log2fc). Surprisingly, the protein expression in 
Western blot was not significantly changed for none of the experimental conditions. The 
protein expression compared to NC siRNA treated cell was 110.0 % ± 9.2 % SEM (p=0.574) 
in miR-132-3p and 80.6 % ± 9.9 % SEM in miR-212-3p treated PMN (p=0.16, both n=9, 
Dunnett’s test, Figure 9-D). According to mirwalk.org it is a predicted target of  
miR-212-3p but none of the target prediction algorithms lists TAX1BP3 as a target of  
miR-132-3p. 
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ROCK2 is a protein which is highly investigated in the context of ND but only mirwalk.org 
lists ROCK2 as a predicted target of miR-132-3p but not of miR-212-3p. Its downregulation 
leads to improved neurite growth and is probably beneficial in different ND (Koch et al. 
2014; Koch et al. 2018). In mass spectrometry it was significantly downregulated for miR-
132-3p (-1.19 median log2 fc) but not changed for miR-212-3p. Western blot showed a trend 
to downregulation for both miRNAs not reaching statistical significance. The protein 
expression in miR-132-3p transfected cells was 86.4 % ± 4.7 % SEM (p = 0.088) and 
86.7 % ± 6.7 % SEM (p = 0.095, both n = 12, Dunnett’s test,  Figure 9-E).  
EPHA5 is a predicted target of miR-212-3p according to microrna.org and mirwalk.org and 
was significantly downregulated for miR-212-3p in SWATH-MS (-1.47 median log2 fc). In 
Western blot it was significantly decreased to 66.4 % ± 12.8 % SEM (p = 0.02) in miR-212-
3p transfected PMN compared to NC siRNA treatment. However, it also showed a similar 
trend in miR-132-3p transfected cells with a decrease to 73.1 % ± 8.6 % SEM not reaching 
statistical significance (p = 0.08, both n = 9, Dunnett’s test, Figure 9-F). 
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5 Discussion 
5.1 Modelling miRNA overexpression in PMN 
This study intended to investigate effects of increased levels of the miR-132-3p and miR-
212-3p in dopaminergic PMN. As the general efficacy of the PMN transfection protocol was 
already demonstrated earlier (Roser et al. 2018b), experiments to identify a suitable 
transfection concentration were performed with three different concentrations of the 
respective miRNA mimics. Transfection with 5 nM was identified as a suitable transfection 
concentration as no toxicity or saturation effect was observed. It was therefore used for both 
miRNAs in all following experiments.  
The ICC and Western blot experiments showed that both miRNA mimics were transfected 
successfully and showed biological effects. The ICC and Western blot experiments revealed 
various effects of miR-132-3p in dopaminergic PMN, whereas the downregulation of 
EPHA5 was the only observed effect after transfection with miR-212-3p mimics. Based on 
the miRNA levels in qPCR, protein regulation and effects observed in ICC, one can conclude 
that the transfection with miRNA mimics is an appropriate in vitro model for the investigation 
of miRNA mediated effects and the involved protein alterations. 
5.2 Possible mechanisms of  increased neurite growth in miR-132-3p 
mimics treated dopaminergic PMN 
Evaluating growth and regeneration of neuronal processes is highly relevant in the field of 
neurodegeneration. In PD, evidence suggests that the first neuropathological events start in 
the dopaminergic axons (Burke and O'Malley 2013). Our results have shown that  
miR-132-3p transfected PMN presented significant increase in neurite length and improved 
neurite regeneration after scratch lesion. Regulation of neurite morphogenesis and 
arborization by miR-132-3p was already demonstrated in cortical, newborn olfactory bulb 
and hippocampal neurons (Vo et al. 2005; Pathania et al. 2012; Magill et al. 2010; Impey et 
al. 2010). Interestingly, these studies either used a knockout model of the whole miR-
132/212 locus or exclusively investigated effects of increased levels of miR-132-3p. The 
neurite growth improving effect was attributed to the downregulation of ARHGAP32, which 
is a predicted target of miR-132-3p and was validated as a target in the context of the cited 
studies. Downregulation of ARHGAP32 activates the Rac-1-Pak signaling pathway leading 
to actin remodeling and neurite growth (Vo et al. 2005; Impey et al. 2010; Wayman et al. 
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2008). Here, we could confirm a downregulation of ARHGAP32 by miR-132-3p but not by 
miR-212-3p mimics in dopaminergic PMN by Western blot. 
Further studies investigated the influence of miR-132-3p and novel mechanisms were 
identified to be involved in the mediation of its effects on axon growth. In dorsal root ganglia 
(DRG) miR-132-3p was shown to extend axon outgrowth via downregulation of RASA1 
(also known as p120-RasGAP) in cell cultures locally in the axon (Hancock et al. 2014). 
Another putative mediator of neurite growth and especially neurite arborization is MECP2. 
It was found downregulated for miR-132-3p in SWATH-MS and Western blot whereas levels 
for miR-212-3p were not changed. Moreover, our SWATH-MS experiments identified the 
significantly regulated GO cluster “Synapse assembly” including MECP2 together with 
GPM6A and SPTBN2 (Table 15). The MECP2 protein is an already validated target both 
for miR-132-3p and miR-212-3p (Klein et al. 2007; Wada et al. 2010; Im et al. 2010). A 
knockout of Mecp2 was demonstrated to lead to improved neurite growth in Mecp2 deficient 
DRG. The downregulation of MECP2 by miR-132-3p could thus be co-responsible for the 
enhanced neurite growth induced by miR-132-3p (Bhattacherjee et al. 2017). However, the 
effects of MECP2 in regulating neurite growth are complex and might be affected by several 
regulatory mechanisms. There is considerable evidence that both – decreased as well as 
increased levels – impair cognition and development. For instance, mutation in the MECP2 
locus lead to the X-linked Rett’s syndrome including massive cognitive deficits. It is also 
reported to be involved in a homeostatic control of BDNF, CREB and miR-132/212 
transcription which all themselves regulate each other. For instance, miR-132-3p and miR-
212-3p are reported to indirectly suppress BDNF expression but also to initiate a BDNF 
disinhibition by targeting the BDNF inhibitor MECP2 (Im et al. 2010). Thereby the miRNAs 
contribute to the homeostasis of BDNF. The expression of CREB is stimulated among 
others also via a disinhibition mediated by miRNA induced downregulation of MECP2. 
Both, the transcription factor CREB and the neurotrophic BDNF, are highly important for 
neurodevelopment and neuronal plasticity – processes where a correct function of miR-
132/212 is also needed. The direct miRNA target MECP2 but also CREB and BDNF are 
likely to be parts of the miR-132/212 influenced mechanisms upon the mentioned processes 
(Feng and Nestler 2010; Im et al. 2010). Additionally, both CREB and BDNF, control the 
transcription of miR-132/212 (Vo et al. 2005; Remenyi et al. 2010).  
Another significantly regulated GO cluster from our SWATH-MS results, features the 
biological process “Rho protein signal transduction”. It includes ROCK2, TAX1BP3 and 
ARHGEF11. Inhibition of ROCK2 has already been described to improve neurite 
outgrowth (Lingor et al. 2007; Fuentes et al. 2008; Koch et al. 2014).  
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The ROCK2 protein was also found downregulated in our analysis as shown by SWATH-
MS after miR-132-3p transfection and showed a similar trend after transfection of both 
miRNAs in Western blot validation studies. This downregulation could be an additional 
mediator of improved neurite outgrowth induced by miR-132-3p. Experiments in zebrafish 
nerve explants also demonstrated an involvement of TAX1BP3 in neurite outgrowth. Its 
siRNA-mediated downregulation led to shorter neurites, but this effect could be rescued by 
an additional inhibition of ROCK (Matsukawa et al. 2018). Although TAX1BP3 was highly 
upregulated in SWATH-MS for both conditions, no alterations of protein expression could 
be observed in Western blot.  
Furthermore, the growth-related protein MAPT (also known as TAU) was upregulated in 
our SWATH-MS results for miR-132-3p transfected PMN but is also a predicted target of 
both miRNA strands. The miR-132-3p is even validated to target MAPT and its deficiency 
is reported to decrease neurite growth in embryonic hippocampal neurons (Dawson et al. 
2001). Thus, the upregulation of MAPT in miR-132-3p transfected PMN is compatible with 
the growth improving effects observed in miR-132-3p treated cultures. On the other hand, 
the validation of MAPT as a target of miR-132-3p in miR-132/212 deficient mice and 
neuroblastoma cells transfected with miR-132-3p mimics is contradictory to the SWATH-
MS results. After transfection with miR-132-3p one would expect a downregulation of 
MAPT, however, it was upregulated in the SWATH-MS analysis for the miR-132-3p 
condition. As both – high levels of miR-132-3p and of MAPT– are associated with improved 
growth upon maturation, a context-dependent regulation of MAPT by miR-132-3p is 
possible. Whereas MAPT may be downregulated by miR-132-3p in mature neurons, it is 
possibly not directly targeted by miR-132-3p in maturing neurons such as the PMN used 
here. Thus, further analysis of MAPT regulation by miR-132/212 in maturing neurons is 
needed. Moreover, the protein is intensively investigated because its aggregation in mature 
neurons was demonstrated to lead to different kinds of ND such as AD and different types 
of aPS; the so called tauopathies. (Smith et al. 2015; Zuo et al. 2016; Dawson et al. 2001; 
Coppede 2012). 
The experiments presented here showed a downregulation of ARHGAP32 and MECP2 by 
miR-132-3p and the same trend was observed for ROCK2. Downregulation of these 
proteins was repeatedly reported to increase neurite growth and could thus be partly 
responsible for the growth improving effects of miR-132-3p on dopaminergic PMN 
observed in ICC experiments. However, to attribute the growth improving effects directly 
to these proteins, further experiments specifically targeting these proteins (e.g. via siRNA) 
are necessary.   
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5.3 miR-132-3p induced improvement of  neurite regeneration in 
dopaminergic PMN and possible underlying mechanisms 
The scratch lesion experiments were performed to further elucidate regeneration abilities of 
dopaminergic neurons with increased levels of miR-132-3p and miR-212-3p. Our results 
indicate that transfection with miR-132-3p mimics – but not with miR-212-3p mimics – led 
to improved regeneration after scratch lesion (measured as sum of the seven longest neurites 
normalized to the NC). Thus, this observation could possibly be influenced by neurite 
growth pathways, in case that neurite growth and neurite regeneration base on common on 
similar pathways and mechanisms. However, experiments with cultured neurons of 
Drosophila revealed that major pathways like PI3K/Akt and TOR were necessary for neurite 
regeneration and sprouting, but not for the initial neurite growth (Marmor-Kollet and 
Schuldiner 2016). Another study in cultures of cortical neuron described morphological 
differences and a different cytoskeletal composition of growth cones of growing and 
regenerating neurons (Blizzard et al. 2007). They also reported that GDNF and BDNF 
enhanced growth of developing but not of regenerating axons indicating the existence of 
different underlying pathways. However, another study observed improved regeneration 
after scratch lesion in GDNF transfected dopaminergic neurons (Roser et al. 2018b). The 
same scratch lesion model in dopaminergic PMN was also used by Saal and colleagues (2015) 
who observed a massively improved neurite regeneration after inhibition of ROCK2 by 
short-hairpin-RNA (shRNA) expressing AAV. As ROCK2 was also downregulated after 
miR-132-3p transfection shown by SWATH-MS and showed a similar trend in the Western 
blot validation, ROCK2 might be one of the mediators of improved neurite regeneration in 
the present model. 
Earlier studies which showed an enhanced regeneration after scratch lesion also investigated 
possible underlying cellular mechanisms. It was observed that the applied regeneration 
improving treatments involved TGF-β-modulated proteasome activity, JNK activity, 
downregulation of the pro-autophagic FOXO3 and activation of the pro survival PI3K-Akt 
signaling pathway (Tonges et al. 2011; Knöferle et al. 2010; Roser et al. 2018b). These 
findings suggest that the observed regeneration after mechanical lesion is at least partly 
mediated by modulation of apoptosis and autophagy. Interestingly, FOXO3 is also a 
validated target of miR-132-3p and miR-212-3p (Byeon et al. 2017; Mehta et al. 2015). Also 
the activation of the PI3K-Akt signaling pathway was described via a miR-132-3p induced 
downregulation of PTEN in a human brain endothelial cell line and primary cortical neurons 
(Gu et al. 2018; Zhao et al. 2018). 
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Taken together, the present literature suggests different targets and pathways influenced by 
increased levels miR-132-3p related to apoptosis and autophagy which could also be partly 
responsible for the effects observed here. To test putative underlying pathways or proteins, 
similar experiments specifically regulating single proteins (e.g. by siRNA) are needed. 
Western blot and SWATH-MS indicated first promising candidates such as ROCK2 or 
PTEN. 
5.4 Transfection with miR-132-3p or miR-212-3p mimics cannot 
protect dopaminergic neurons from MPP+ induced toxicity 
Research strives to provide neuroprotective therapies to PD patients who are currently only 
treated symptomatically. An optimal disease-modifying therapy would slow down the 
progression of the degenerative processes. Toxicity induced by MPP+ specifically targets 
dopaminergic neurons which are the predominantly affected cell type in PD. It leads to 
massive oxidative stress by complex I inhibition which is also suspected to play a role in PD 
pathogenesis (Kopin 1992; Dexter and Jenner 2013; Puspita et al. 2017). In the present 
experiments, none of the miRNA mimics transfected conditions improved the survival of 
the dopaminergic neurons. In earlier studies, inhibition of ROCK2 by transduction with 
shRNA expressing AAV was shown to improve survival of dopaminergic neurons after 
MPP+ treatment (Saal et al. 2015). They thereby applied a much more specific treatment 
targeting a single protein than we achieved by the transfection with miRNA targeting an 
incalculable number of targets. The possible miRNA mimics induced downregulation of 
ROCK2 might be insufficient to significantly influence neuronal survival after MPP+ 
treatment. Furthermore, the influence of other pathways on neuronal survival affected by 
the miRNA treatment cannot be estimated. 
Another mechanisms of improved neuronal survival are the earlier discussed downregulation 
of FOXO3 or activation of the PI3K-pathway described in a similar experiment with PMN 
(Roser et al. 2018b). Among the discussed targets, ROCK2 is the only one detected in the 
SWATH-MS analysis where it was downregulated in miR-132-3p transfected PMN with a 
similar trend in Western blot. Other proteins like the PI3K pathway controlling PTEN or 
FOXO3 were neither detected in SWATH-MS nor were they investigated in Western blot 
here. Thus, it is unclear whether they are regulated as suggested in the present model. Besides, 
our results might indicate an insufficient regulation of the relevant pathways in relation to 
the applied toxin. Nevertheless, earlier studies in PMN with miR-182-5p and miR-183-5p 
treated with the same concentrations of MPP+ and miRNA mimics, however, did observe 
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beneficial effects in miRNA transfected PMN (Roser et al. 2018b). The applied MPP+ dosage 
of 2 µM is therefore probably not generally excessively toxic but leaves leeway for possible 
miRNA mediated neuroprotective effects as observed by Roser and colleagues. 
Consequently, the effects of the treatment with miRNA mimics used in the present study 
might be not specific enough or insufficient in their regulation of ROCK2 or other not 
investigated mechanisms to induce any observable effects against the dopaminergic 
neurotoxicity induced by MPP+.  
Other reports described effects of another miRNA from the miR-132/212 cluster. Sun and 
colleagues published a comprehensive study on the effects of the counter strand miR-212-
5p, which they observed to be downregulated both in MPTP in vivo and MPP+ in vitro models. 
Injection of miR-212-5p mimics into the lateral ventricle was shown to protect dopaminergic 
neurons from MPTP induced cell death. Survival of dopaminergic neurons was also 
improved in MPP+ treated SH-SY5Y cells with increased levels of mR-212-5p. They 
attributed the observed effect to the downregulation of the cytosolic SIRT2 which was 
upregulated after MPTP and MPP+ treatment but downregulated by the miR-212-5p mimics. 
The neuroprotective effect was probably mediated by consecutive downregulation of p53 
(Sun et al. 2018). Earlier studies also demonstrated neuroprotective effects of SIRT2 
inhibitors (Outeiro et al. 2007). In the SWATH-MS analysis the expression of SIRT2 was 
not altered for none of the miRNA neither is it a predicted target of the miR-132-3p or miR-
212-3p strands used in this study. However, it is interesting to notice that the 5p-counter 
strands have neuroprotective effects as they are transcribed as common pri-miRNA even 
though the 3p strands are reported to be the predominantly processed miRNAs. 
The experiment with MPP+ induced cell toxicity was also conducted with PMN transfected 
with other miRNA – namely the miR-7b-5p and miR-129-2-3p – previously identified as 
putative players in dopaminergic development in vitro (Roser 2016). In our experiments, the 
aforementioned miRNAs did not alter survival of dopaminergic neurons either. Other 
studies however, did observe attenuated cell death for miR-7b-5p in SH-SY5Y cells (Li et al. 
2016) and in cortical neurons transduced with miR-7b carrying AAV (Choi et al. 2014). Li 
and colleagues also attributed the attenuated cell death to the downregulation of SIRT2 and 
BAX which they found downregulated in Western blot. As miR-7b-5p also targets  
α-synuclein, it has been discussed as a potential therapeutic agent in PD (Titze-de-Almeida 
and Titze-de-Almeida 2018). For miR-129 and miR-132, there are no comparable studies 
available.  
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Although the mentioned studies investigating effects of miR-7b or miR-212-5p are partially 
related to the experiments presented here, they were fundamentally different in several 
important aspects. Sun and colleagues used the counter strand of the miR-212-3p that was 
used here. The studies on miR-7b used different models, different miRNA vehicles or did 
not focus exclusively on dopaminergic neurons. Nevertheless, the reported effects of miR-
212-5p or miR-7b-5p make these miRNAs promising therapeutic agents against MPP+ 
induced dopaminergic degeneration. 
5.5 SWATH-MS and target validation in Western blot 
The SWATH-MS analysis served as a discovery method for altered protein abundancies 
related to treatment with miRNA mimics in PMN. In this context, it is important to highlight 
that miRNA regulate protein levels by binding to the respective mRNA before translation or 
further post translational modifications take place (Winter et al. 2009; Wang et al. 2013b). 
Changes induced by miRNA mimics can therefore be hidden by compensatory effects such 
as a slower degradation of the respective proteins. Furthermore, the measured differences 
between the experimental conditions can be the result of direct effects of the transfected 
miRNA mimics but can also due to a reactive counter regulation or downstream effects of 
affected pathways. Finally, by quantitative protein measurement, it is not possible to make 
any statements on the function of proteins, i.e. activities of kinases and other enzymes.  
The present SWATH-MS results revealed an interesting overlap of miRNA predicted targets 
and regulated proteins. Out of 3,311 quantified proteins 101 (3.1 %) were regulated by miR-
132-3p and 83 (2.5 %) by miR-212-3p. Targetscan.org predicts 414 targets for the mmu-miR-
for these miRNAs. Out of these 414 predicted targets, 111 could be detected and quantified 
in our experiments. From those, six proteins that are also predicted targets of the miR-
132/212 cluster were indeed regulated. Finally, four targets were at the same time predicted 
and downregulated – as expected in the canonical miRNA regulation of the transcriptome 
and the potential modulation in protein expression. Those were PAPOLA and ARHGEF11 
(downregulated by both miRNAs), as well as RRAS2 and MECP2 (only regulated by miR-
132-3p).  
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The limited overlap of predicted targets and quantified proteins might be because the used 
cell lysates from PMN only include two different cell types – GABAergic (90-95 %) and 
dopaminergic neurons (5-10 %). They do thus not include all possible proteins. Furthermore, 
the number of quantified proteins was reduced technically as only proteins identified in every 
run and sample were considered for quantification. Moreover, data independent acquisition 
methods such as SWATH-MS reveal predominantly differences of the most abundant 
proteins. Less abundant proteins – which are probably more expressed in non-neuronal 
tissue or more mature cells – may not have been expressed sufficiently to be quantified. 
Other methods of mass spectrometry analysis concentrating on lists of predefined targets 
like peptide centric scoring (also called targeted data extraction) can be three- to ten-fold more 
sensitive than SWATH-MS and would thus be more suitable to investigate less abundant 
proteins and peptides (Ludwig et al. 2018). 
It is important to mention that the target prediction databases employed here are mainly 
based on matching sequences of the miRNAs’ seed regions to those of mRNAs, and thus, 
still include many false-positive and non-validated proteins. During the statistical analysis of 
SWATH-MS data, it was also noticed that the three different PMN cultures differed quite 
substantially from each other. Therefore, it is likely that several regulated proteins did not 
reach statistical significance as the variability between the different cell cultures was too high. 
On the other hand, our SWATH-MS experiments detected MECP2, a predicted and 
repeatedly validated target of miR-132-3p (Im et al. 2010; Wada et al. 2010; Klein et al. 2007). 
Besides, there are no comparable studies published to estimate the quality and results of this 
SWATH-MS. A recent proteome analysis of the nucleus suprachiasmaticus from miR-
132/212 deficient mice analyzed the time-of-day dependent fluctuation in the knockout 
proteome. They identified among others Ephrin Receptor Signaling, RhoGDI signaling and 
Remodeling of epithelial tight junctions as time-of-day dependent GO clusters in the miR-132/212 
knockout mice, which fits to KEGG pathways and targets discussed in the context of the 
present SWATH-MS analysis (Mendoza-Viveros et al. 2017). 
An interesting study in this context investigated the hippocampal mRNA expression of miR-
132/212 deficient, miR-132 and miR-212 overexpressing mice. They only considered 
mRNAs as targets which were downregulated in the overexpressing animals, upregulated in 
the knockout mice and predicted by microRNA.org. This resulted in 13 targets regulated by 
miR-132 and one target regulated by miR-212. Five of the miR-132 regulated targets were 
also detected in the present SWATH-MS analysis but none of them was regulated 
significantly. The only protein fulfilling all three criteria for miR-212 was STX1A which was 
not detected in the present SWATH-MS (Hansen et al. 2016).  
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Mass spectrometry proteomics with SWATH analysis can record treatment induced protein 
alterations on a large scale and unbiased for the selection of proteins. However, it quantifies 
protein expression without a loading control to normalize for varying loading amounts. 
Therefore, single proteins related to neurite growth and regeneration were selected for 
validation by Western blot where protein expression can be normalized to a loading control, 
such as GAPDH which is not altered by the applied treatment. The experimental protocol 
of transfecting the PMN with the miRNA mimics until the lysis of the cells using RIPA 
buffer and a sonication device, was the same for the SWATH-MS and the Western blot 
samples. In the cases of MECP2 and EPHA5, results from SWATH-MS could be validated 
successfully by Western blot. MECP2 was downregulated by miR-132-3p in both 
experiments and EPHA5 was downregulated for miR-212-3p in both cases.  
ROCK2 was significantly decreased after miR-132-3p transfection in SWATH-MS. In 
Western blot it showed a similar trend for both miRNAs, yet no significant regulation. In 
this context, it is important to underline that effects of kinases like ROCK2 depend more on 
their activity than on their absolute quantity. Its activity can be regulated, for instance, by 
deletion of the auto-inhibiting carboxyl-terminal region (constitutive activation), binding of 
RHOA for (transient disinhibition) and phosphorylation (Koch et al. 2018). This means that 
the physiological effects of ROCK2 must be additionally assessed by measuring its activity 
and by measuring the modulation of its downstream targets. 
Besides, TAX1BP3 – which was reported to be necessary for neurite outgrowth (Matsukawa 
et al. 2018) – was selected for validation. In SWATH-MS, it was highly upregulated and was 
among the ten most upregulated proteins in both conditions. This effect could not be 
reproduced in Western blot, where no significant differences were observed. For  
miR-212-3p there was even a mild (non-significant) trend towards decreased TAX1BP3 
expression. Since Western blot is a technique widely used to validate proteomics results – 
despite of its technical limitations – the TAX1BP3 results obtained by Western blot with ten 
independent PMN cultures are more credible than the proteomics results. Interestingly, 
TAX1BP3 is a predicted target of miR-212-3p, but not of miR-132-3p.  
All in all, our Western blot analyses could confirm the regulation of most of the selected 
proteins. Nevertheless, the SWATH-MS results revealed more targets than analyzed and 
discussed here. Because of limitations in time and scope, we reduced our selection of 
validated proteins to those directly related to neurite growth and regeneration.  
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5.6 Possible mechanisms and pathways mediating the effects 
observed in ICC 
In order to link regulated targets and related pathways of miR-132-3p and miR-212-3p to 
each other and to the neurite growth and neurite regeneration improving effects observed in 
ICC, observations from SWATH-MS and Western blots were compiled alongside with an 
extensive literature research. Therefore, reports mentioning miR-132-3p and miR-212-3p in 
the context of neurite growth, regeneration and maturation as well as three different target 
prediction databases were considered. The proposed protein interactions and pathways are 
displayed in Figure 10. The results from the named experiments and specific references from 
literature research for all discussed targets are summarized in the appendix in Table A4. 
The complex effects of altered MECP2 levels and the feedback loop controlling  
miR-132/212 transcription were discussed earlier and are not implemented in the figure. 
TAX1BP3 is not included in the figure as its results from SWATH-MS and Western blot 
were contradictory. Moreover, this protein and its interactions are still poorly understood. 
So far, it was only reported that TAX1BP3 is necessary for neurite growth in zebrafish nerve 
explants. It possibly increases neurite growth by inactivation of RHOA via rhotekin (RTKN). 
Besides, impaired neurite growth after TAX1BP3 siRNA treatment can be rescued by ROCK 
inhibition (Matsukawa et al. 2018). Regulation of cell development via MAPT was also not 
implemented due to the contradictions discussed. 
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Figure 10 Proposed proteins and pathways altered by overexpression of miR-132-3p 
and miR-212-3p possibly mediating the effects observed in ICC experiments 
Targets of miR-132-3p and miR-212-3p validated in this thesis or other publications are summarized and linked 
to their influence on neurite growth and neurite regeneration. The green or red arrows indicate the respective 
protein regulation after increased levels of miR-132-3p and miR-212-3p. Proteins investigated in the present 
study are highlighted in yellow. This simplified figure does not differentiate between influences on neurite 
growth and neurite regeneration as many of the pathways were described to be involved both in neurite growth 
and regeneration. Table A4 summarizes experimental results, target prediction and results from other 
publications for all targets shown in this figure. 
According to the pathways depicted here, by targeting PTEN, miR-132-3p induces a 
disinhibition of the PI3K signaling pathway and a consequently upregulation of its targets 
like CREB, mTOR or AKT. The pathway is especially important for the regulation of the 
cell cycle and cell proliferation. It is considered as a major pro-survival pathway – alterations 
were therefore also frequently observed in cancer studies (Gu et al. 2018; Wong et al. 2013; 
Liu et al. 2017; Jin et al. 2012). Nevertheless, inhibition of PTEN was demonstrated to induce 
neurite growth and, in particular, to enhance neurite regeneration. In this context, a 
therapeutic inhibition of PTEN in CNS disorders and after axonal injury is also discussed 
(Ohtake et al. 2015; Park et al. 2008). On the other hand, experiments with Drosophila 
mushroom body neurons revealed that PI3K/Akt and TOR were necessary for neurite 
regeneration and sprouting, but not for the initial neurite growth (Marmor-Kollet and 
Schuldiner 2016).  
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The transcription factor FOXO3 can be inhibited by the PI3K downstream target AKT but 
is also a direct target of both miR-132-3p and miR-212-3p. As it has pro-apoptotic effects, 
its downregulation is linked to improved neuronal survival and neurite regeneration, but also 
to carcinogenesis (Roser et al. 2018b; Santo et al. 2013; Wong et al. 2013; Mehta et al. 2015; 
Wang et al. 2013a). The miR-132-3p induced anti-apoptotic effects of increased PI3K and 
decreased FOXO3 activity were even used to explain the increased apoptosis in AD. In a 
study using brain tissue of AD patients, the levels of miR-132-3p and miR-212-3p were 
observed to be decreased depending on the disease state whereas the pro-apoptotic levels of 
PTEN, PI3K and FOXO3 increased. The direct influence of miR-132/212 on these targets 
was confirmed in different neuronal cell cultures and finally used as possible causal 
explanation for the increased neuronal apoptosis observed in AD (Wong et al. 2013). An 
involvement of these apoptosis and cell cycle related pathways also fits to the observed 
alterations of miR-132/212 expression in various types of cancer. 
Another validated target of miR-132-3p, is RASA1. Downregulation of RASA1 and 
subsequently neurite outgrowth was observed in various models and is linked to an activation 
of ERK, RAS and MAPK signaling pathway. Signaling through RAS and MAPK are among 
the most important mechanisms for cell growth (Hancock et al. 2014; Anand et al. 2010; 
Antoine-Bertrand et al. 2016; Lei et al. 2015). The involvement of RASA1 also fits to miR-
132/212 related observations in cardiovascular diseases and cancer. Interestingly, activation 
of the ERK1 pathway was also reported to increase miR-132 levels (Chen et al. 2012). 
It is remarkable that RAC1, CDC42 and RHOA – three major GTPases controlling 
cytoskeleton dynamics – are involved in the proposed pathways. The protein ARHGAP32 
is a repeatedly validated target of miR-132-3p. Downregulation of ARHGAP32 consequently 
leads to an upregulation of CDC42, RAC1 and RHOA (Okabe et al. 2003; Moon et al. 2003; 
Zhao et al. 2003; Nakazawa et al. 2003; Impey et al. 2010). The activation of RAC1 is the 
most frequently used mechanism to explain the increased neurite length after increased levels 
of miR-132-3p (Impey et al. 2010; Vo et al. 2005; Wayman et al. 2008). Besides, also the 
overexpression of CDC42 is described to increase neurite outgrowth (Matsukawa et al. 2018).  
On the other hand, the ARHGAP32 target RHOA must be inactivated for a subsequent 
inactivation of ROCK to increase neurite growth (Matsukawa et al. 2018; Koch et al. 2014). 
Evidently, the protein interactions depend to a large extent on the model employed. In their 
model of hippocampal neuron cultures, Impey and colleagues did not observe altered RHOA 
levels neither after overexpression of miR-132-3p nor after specific downregulation of 
ARHGAP32. 
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Moreover, the activation of RHOA by ARHGAP32 downregulation might also be vanished 
by the simultaneous activation of CDC42, which is a known RHOA inhibitor (Matsukawa 
et al. 2018). RHOA might further be inactivated via inactivation of ARHGEF11, which is a 
predicted target both for miR-132-3p and miR-212-3p and was also downregulated for both 
miRNAs in SWATH-MS. Furthermore, downregulation of ARHGEF11 was shown to 
improve neurite growth via inactivation of RHOA (Lin et al. 2011). 
The proposed pathways and mechanisms induced by miR-132/212 are based on experiments 
and literature research in very specific and often highly artificial models. Results can 
dependent on the model, the disease and on the technique of miRNA transfection, 
transduction or knockout. Nevertheless, the summarized results indicate that the miR-
132/212 cluster – and especially miR-132-3p – which was predominantly investigated – 
regulated some of the most important pathways for cell growth, cell proliferation and cell 
survival. This fits very well to the upregulation of miR-132-3p in maturing PMN initially 
observed by Roser and colleagues (Roser 2016; Roser et al. 2018b).  
5.7 miR-132-3p and miR-212-3p show different effects in neurite 
growth and regeneration experiments 
Interestingly, miR-132-3p was the only miRNA which induced significant effects in the 
performed ICC experiments. As the sequence of both miRNAs is very similar and they even 
share an identical seed sequence – which is especially important for binding to the target 
mRNA – one would generally assume a large overlap of targets and similar effects. However, 
miR-212-3p as well as a combination of miR-132-3p and miR-212-3p did not alter neurite 
growth, regeneration or cell survival after MPP+ treatment. In the proteomics analysis miR-
132-3p regulated more targets and GO clusters than miR-212-3p and significantly affected 
three KEGG pathways. A series of different hypothesis aims to explain this interesting 
observation. 
First, we hypothesize that the effects on neurite growth of miR-132-3p are intimately linked 
to a downregulation of ARHGAP32, which is neither a predicted target of miR-212-3p nor 
was its expression significantly changed in the present experiments. The unchanged levels of 
ARHGAP32, MECP2 and other miR-132-3p affected pathways discussed earlier, could thus 
explain why neurite growth is not altered in miR-212-3p treated PMN. However, the 
neutralization of miR-132-3p effects on growth and regeneration in the co-transfected 
condition drew our attention to a possible combinatorial regulation in the effects of the two 
miRNAs.  
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On the one hand, the findings in the co-transfected condition could be related to the 
treatment with an increased amount of miRNA mimics. As the cells are transfected with 
double the amount of miRNA mimics in that condition, possible disturbances of the miRNA 
machinery might occur. Moreover, even though both miRNAs are transcribed together, the 
mature miRNA strands can be expressed differently. In studies with hippocampal neuron 
cultures miR-132-3p was the only mature miRNA strand from the miR-132/212 locus 
(Magill et al. 2010). Thus, it could be that unexplored mechanisms selecting the miR-132-3p 
strand as the only active mature miRNA strand, also reduce the effects of transfected  
miR-212-3p mimics. Measurement by qPCR of miR-212-3p levels 24 hours after transfection 
showed massively increased levels compared to NC. Although, considering the large amount 
of transfected miRNA mimics (relatively to endogenous levels) and the miR-212-3p 
mediated effects in SWATH-MS and Western blot, a specific counter regulation against 
transfected miR-212-3p is not very likely. 
On the other hand, it is also imaginable that miR-212-3p induces pathways to limit effects 
of miR-132-3p as a sort of miRNA cluster inherent counter regulation. A possible 
mechanism of miR-212-3p counter regulation could be the repression of EPHA5. In the 
present SWATH-MS and Western blots EPHA5 was downregulated in PMN transfected 
with mimics of miR-212-3p. It is also a predicted target of both miRNAs. Signaling via the 
Ephrin tyrosine kinase receptors is involved in axon guidance by inducing a collapse or 
repulsion of the growing neurite.  
Several studies report improved neurite growth after downregulation of EPHA5 and 
increased EPHA5 signaling was shown to decrease the average neurite length in cortical 
neurons (Gao et al. 1998). Moreover, investigations in retinal ganglion cells (RGC) showed 
that EPHA5 signaling led to increased RHOA activity and decreased RAC1 activity – the 
opposite regulation of the growth improving effects related to miR-132-3p. Interestingly, 
inhibition of ROCK prevented the typical EPHA5 induced growth cone collapse in the same 
experimental setting (Wahl et al. 2000). Other Ephrin receptor isoforms like EPHB2 were 
also reported to inactivate the RAS-MAPK pathway via an activation of RASA1 (Elowe et 
al. 2001). According to these reports, decreased EPHA5 receptor expression – like observed 
for miR-212-3p in Western blot and SWATH-MS – would rather lead to increased neurite 
outgrowth. 
However, in other studies EPHA5 signaling was reported to be beneficial for neurite growth. 
In a similar model of TH positive sympathetic neuroblast, it could be demonstrated that 
EPHA5 signaling had a reverse effect and could improve neurite growth (Gao et al. 2000). 
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Moreover, the need of EPHA5 activation (by its ephrin-A5 ligand) for dopaminergic axon 
outgrowth was demonstrated in rat PMN (Cooper et al. 2009). According to the observations 
of the two above mentioned studies., the decreased levels of EPHA5 observed in SWATH-
MS and Western blot could lead to decreased neurite growth and could thus be a possible 
explanation for the neutralized effects of miR-132-3p in the co-transfected condition. 
Following this hypothesis, however, one could even expect decreased neurite growth and 
regeneration in the miR-212-3p transfected condition. 
Notwithstanding, the present experiments did only measure expression of the EPHA5 
receptor and did not investigate whether the observed reduction of the EPHA5 receptor also 
leads to reduced EPHA5 activity and downstream signaling. Thus, it would be necessary to 
further examine EPHA5 effects in the present model. Activity of EPHA5 should be 
measured as well as expression levels of possible downstream targets such as RHOA and 
RAC1 in EPHA5 siRNA treated cells. Furthermore, evaluation of neurite growth and 
regeneration would be ideally repeated with EPHA5 siRNA and with miR-132-3p plus 
EPHA5 siRNA treated conditions. Thereby, one could test whether miR-212-3p induced 
EPHA5 downregulation is indeed involved in the neutralization of miR-132-3p effects on 
neurite growth and regeneration.  
As discussed above, the present experiments cannot explain the underlying mechanisms of 
the neutralization of miR-132-3p effects on neurite growth and regeneration in the co-
transfected condition. Literature compilation on the topic showed that the majority of studies 
focused exclusively on miR-132-3p. On the other hand, miR-212-3p is often mentioned in 
the context of knockout models, where the whole miRNA locus was deleted, but is rarely 
investigated separately. Consequently, the number of validated targets is much larger for 
miR-132-3p than for miR-212-3p (Wanet et al. 2012). A small RNA sequencing of  
miR-132/212 overexpressing mice showed much more regulated mRNA for miR-132 (928) 
than for miR-212 (58) (Hansen et al. 2016). To a lesser extent, this tendency was also 
observed in the present SWATH-MS and underlines the dominance of miR-132-3p not only 
in literature. Taken together, the different effects of the miRNA mimics used here, follow 
the pattern of other scientific publications. Furthermore, they indicate a strong dominance 
of the miR-132 strand in the mediation of effects related to the miR-132/212. However, this 
might be a biased impression, as most studies exclusively investigated the miR-132-3p strand. 
Several hypotheses were discussed which lead to the observed effects and more experiments 
need to be performed to determine the underlying mechanisms. Limitations of the miRNA-
mimic model as well as a mechanistic counter regulation possibly involving EPHA5 are 
among the potential causes of the observed effects. 
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5.8 Concluding remarks 
miRNAs are investigated in many different models and diseases. As parts of the epigenetic 
machinery their transcription and activity can be influenced by the environment and these 
alterations can even be transmitted to following generations. This discovery has opened new 
fields for the investigation of etiology, risk factors and pathogenesis of diseases. 
Highly interesting is the use of miRNAs as therapeutic agents or targets. A lot of studies with 
animal models suggested possible beneficial effects of miRNA replacement or inhibition. 
For instance, replacement of AAV transduced miR-132 improved the survival in a mice 
model of HD (Fukuoka et al. 2018). Furthermore, replacement of miR-7 is discussed as 
(possibly disease modifying) therapy for PD patients. The miRNA targets α-synuclein and 
was also shown to have neuroprotective effects which could not be confirmed in the 
experiments of this study (Titze-de-Almeida and Titze-de-Almeida 2018).  
Exogenous replacement of miRNA or their targeted downregulation e.g. via siRNA would 
be especially practical if the miRNA alteration would be the actual origin of the disease. Even 
though manipulation of miRNA levels can have beneficial effects in several models as 
discussed earlier, they always target incalculable many mRNA. Referring to the mechanisms 
regulated by miR-132-3p with enhanced cell survival or cell growth, introducing exogenous 
miRNA mimics would probably also mean to elevate the risk of cancer genesis. This would 
mean an intolerable side effect, especially in relatively slow progressing ND like PD. 
Moreover, miR-132-3p targets NURR1 – a protein which is found downregulated in PD 
patients and is discussed as a putative replacement agent in PD therapy. Thus, it is unclear 
whether an overexpression (improving growth and regeneration) or downregulation of miR-
132-3p (rescuing NURR1) would be more promising for PD patients (Decressac et al. 2013).  
Nevertheless, a review from 2017 listed four inhibitors and three mimics of miRNA which 
made it to clinical phase I or even phase II trials. Treatment indications are different 
neoplasia, scleroderma and Hepatitis C (Rupaimoole and Slack 2017). More applications for 
patents try to protect the idea of “miRNA as novel therapeutic targets and diagnostic 
biomarkers” in PD (in particular the miR-132/212 cluster, WO2014018650) and specifically 
for the miR-132/212 cluster in cardiac disorders (WO2013034653A1). Although, an 
evaluation of the first named patent soberly underlined the unsolved problems and obstacles, 
patents and possibly following financial support can help to continue the promising research 
on miRNA in neurodegenerative diseases (Hesse and Arenz 2014). In this context, the  
miR-132/212 was demonstrated to have a broad influence on various important cell signaling 
pathways.  
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6 Summary 
All experiments were performed with the idea of gaining more knowledge on the effects of 
the miR-132/212 cluster in dopaminergic PMN. Therefore, PMN were transfected with the 
two mature strands miR-132-3p and miR-212-3p and their influence on growth, regeneration 
and neuroprotection was analyzed. Furthermore, the underlying mechanisms of the effects 
of these miRNAs were investigated to better understand how neurite growth and 
regeneration processes are regulated and to possibly identify interesting proteins controlling 
this mechanism for future therapeutic use. Based on these results, miR-132-3p and  
miR-212-3p were to evaluate as putative therapeutic agents or targets in PD. 
The experiments showed that only increased levels of miR-132-3p improved neurite growth 
and neurite regeneration in dopaminergic PMN. However, transfection with miR-212-3p or 
with both miRNAs combined did not alter growth respectively regeneration compared to 
NC siRNA treatment. None of the three experimental conditions could protect 
dopaminergic neurons from MPP+ toxicity. SWATH-MS indicated an involvement of major 
growth regulating pathways. Several growth, maturation or regeneration related proteins 
were demonstrated to be regulated by the applied miRNA transfection in Western blot 
analysis of PMN lysates. An extensive literature research indicated more targets of the two 
miRNAs and possibly related pathways investigated in other models but related to the 
observations in PMN. 
On the one hand, improved growth or regeneration as induced by increased levels of  
miR-132-3p are possibly beneficial in diseases like PD. On the other hand, other targets of 
this miRNA were reported to be essential and probably even lacking in PD patients’ 
dopaminergic neurons and must thus not be downregulated by overexpression of the 
miRNA. Taken together, a generally beneficial effect of increased levels of these miRNAs in 
PD or other diseases is doubtful. However, identification of targets and pathways under their 
control can extend the knowledge on neuron maturation and regeneration possibly leading 
to interesting targets for new therapeutic approaches.  
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7 Appendix 
Table A1 The 15 most significantly affected KEGG pathways in mice according to 
seed-sequence-based target prediction of miR-132/212 targets by targetscan.org 
KEGG pathway Term p-Value 
mmu05200 Pathways in cancer 7.1E-6 
mmu05215 Prostate cancer 1.0E-4 
mmu05213 Endometrial cancer 2.1E-4 
mmu04550 Signaling pathways regulating pluripotency of stem cells 4.6E-4 
mmu04350 TGF-beta signaling pathway 5.0E-4 
mmu05210 Colorectal cancer 6.4E-4 
mmu04360 Axon guidance 1.3E-3 
mmu05217 Basal cell carcinoma 1.9E-3 
mmu04390 Hippo signaling pathway 3.6E-3 
mmu04520 Adherens junction 6.8E-3 
mmu04068 FoxO signaling pathway 6.9E-3 
mmu04010 MAPL signaling pathway 8.9E-3 
mmu04310 Wnt signaling pathway 9.0E-3 
mmu05221 Acute myeloid leukemia 1.4E-2 
mmu04012 ErbB signaling pathway 1.5E-2 
 
Table A2 Overlap of regulated targets from SWATH-MS and targets predicted by 
three different target prediction databases 
Predicted and regulated targets of  
miR-132-3p 
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Predicted and regulated targets of  
miR-132-3p 
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Table A3 Significantly involved GO clusters of targets regulated differentially in 
SWATH-MS 










cell layer morphogenesis 
1.57E-02 2 GO:0006412~translation 5.59E-03 
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Table A4 Summary of results from SWATH-MS and Western blots and references for the discussed proteins and pathways 
Legend: ↓ downregulation;  ↑ upregulation  ~ unchanged expression  + predicted target  - not a predicted target 
Target 
(Alias names) 
miR-132-3p miR-212-3p Results from this thesis 











































SWATH-MS Western blot 
ARHGAP32  
(p250GAP, RHG32) 





Target of miR-132-3p 
(Vo et al. 2005; Impey et 
al. 2010; Wayman et al. 
2008) 
Inactivates CDC42, RAC1 and RHOA 
(Okabe et al. 2003; Moon 
et al. 2003; Zhao et al. 
2003; Nakazawa et al. 
2003; Impey et al. 2010) 
ARHGEF11 
(PDZ-RHOGEF) 




Inhibition increases neurite outgrowth (Lin et al. 2011) 
Overexpression decreases spine density (Mizuki et al. 2016) 
Activates RhoA and subsequently 
ROCK 
(Sai et al. 2014; Wang et 
al. 2018b) 




Inactivated by ARHGAP32 
(Zhao et al. 2003; Okabe 
et al. 2003; Nakazawa et 
al. 2003) 
Inactivates RHOA (Matsukawa et al. 2018) 





EPHA5 signaling decreases neurite 
length  
(Gao et al. 1998) 
EPHA5 signaling increases neurite 
length in TH+/dopaminergic neurons 
(Gao et al. 2000; Cooper 
et al. 2009) 


































miR-132-3p miR-212-3p Results from this thesis 











































SWATH-MS Western blot 
FOXO3 + + - + + + not detected --- 
Target of miR-132, Target of the miR-
132/212 cluster 
(Mehta et al. 2015; Wong 
et al. 2013) 
Inhibited by the PI3K downstream 
target AKT 
(Santo et al. 2013) 
Downregulation of FOXO3 has anti-
apoptotic / pro survival effects and 
improves neurite growth and 
regeneration 
(Roser et al. 2018b; 
Wong et al. 2013; Wang 
et al. 2013a) 





Target of miR-132-3p and miR-212-3p 
(Im et al. 2010; Wada et 
al. 2010; Klein et al. 
2007) 
PTEN + + + + + - not detected --- 
Target of miR-132-3p, Inhibition works 
anti-apoptotic  
(Jin et al. 2012; Gu et al. 
2018; Wong et al. 2013) 
Activated by ROCK (Li et al. 2005) 
Inhibition leads to increased neurite 
growth and specially to enhanced 
neurite regeneration 
(Park et al. 2008; Ohtake 
et al. 2015) 
RAC1 - - - - - - not detected --- 
Inactivated by ARHGAP32 
(Zhao et al. 2003; Okabe 
et al. 2003; Moon et al. 
2003; Impey et al. 2010) 
Overexpression increases neurite 
outgrowth 
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SWATH-MS Western blot 
RASA1 
(p120GAP) 
+ - + + - - 
miR-132-3p: ~ 
miR-212-3p: ~ 
--- Target of miR-132-3p 
(Hancock et al. 2014; 
Anand et al. 2010; 
Antoine-Bertrand et al. 
2016; Lei et al. 2015) 




Activated by ARHGEF11 (Wang et al. 2018b) 
Inactivated by ARHGAP32 
(Okabe et al. 2003; Moon 
et al. 2003; Nakazawa et 
al. 2003) 
Inactivated by CDC42 (Matsukawa et al. 2018) 
Downregulation of RHOA leads to 
neurite outgrowth 
(Luo 2000; Govek et al. 
2005; Hall and Lalli 2010) 
Activator of ROCK, inhibits neurite 
outgrowth 
(Nakayama et al. 2000) 
ROCK2 - - + - - + 
miR-132-3p: ↓ 
miR-212-3p: ~ 
miR-132-3p:  ~ 
miR-212-3p:  ~ 
ROCK inhibition leads to increased 
neurite growth 
(Nakayama et al. 2000; 
Koch et al. 2014) 
MAPT 
(TAU) 




Tau is a target of miR-132-3p and miR-
132/212 deficiency promotes tau 
aggregation 
(Smith et al. 2015) 
Overexpression increases neurite growth (Zuo et al. 2016) 
Tau deficiency decreased neurite growth (Dawson et al. 2001) 





Inactivates RHOA via rhotekin 
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